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A B S T R A C T
Background
Natalizumab (NTZ) (Tysabri®) is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier, thus reducing
inflammation in central nervous system, and has been approved worldwide for the treatment of relapsing-remitting multiple sclerosis
(RRMS).
Objectives
To evaluate the efficacy, tolerability and safety of NTZ in the treatment of patients with RRMS.
Search methods
We searched the Cochrane Multiple Sclerosis Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL,
The Cochrane Library, 2010, Issue 1), MEDLINE (PubMed) and EMBASE, all up to 19 February 2010, and bibliographies of papers.
Handsearching was carried out. Trialists and pharmaceutical companies were contacted. Furthermore, the websites of US Food and
Drug Administration (FDA), the European Medicines Evaluation Agency (EMA) and the National Institute for health and Clinical
Excellence (NICE) were also checked.
Selection criteria
All double-blind, randomised, controlled trials analysing more than a single infusion of NTZ (dosage > 3 mg/kg intravenous infusion
every 4 weeks), also including its use as add-on treatment, versus placebo or other drugs in patients with RRMS. No restrictions on
the basis of duration of treatment or length of follow up.
Data collection and analysis
Three reviewers independently selected articles whichmet the inclusion criteria. Disagreements were solved by discussion. Two reviewers
independently extracted the data and assessed the methodological quality of each trial. Missing data was sought by contacting principal
authors and Biogen Idec, through Biogen-Dompé Italia.
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Main results
Three studies met the inclusion criteria. These included one placebo-controlled trial (942 patients) and two add-on placebo-controlled
trials, i.e. one plus glatiramer acetate (110 patients) and the second plus interferon beta-1a (1171 patients).
This review assessed the efficacy, tolerability and safety of NTZ in patients with RRMS. Data was conclusive with respect to efficacy
and tolerability, but not safety. As far as efficacy is concerned, the results showed statistically significant evidence in favour of NTZ for
all the primary outcomes and for the secondary ones where data was available. NTZ reduced the risk of experiencing at least one new
exacerbation at 2 years by about 40% and of experiencing progression at 2 years by about 25% as compared to a control group. MRI
parameters showed statistical evidence in favour of participants receiving NTZ. Infusion reactions, anxiety, sinus congestion, lower
limb swelling, rigors, vaginitis and menstrual disorders were reported as adverse events (AEs) more frequently after NTZ treatment. In
this review NTZ was found to be well tolerated over a follow-up period of two years: the number of patients experiencing at least one
AE (including severe and serious AEs) during this period did not differ between NTZ-treated patients and controls. Safety concerns
have been raised about Progressive Multifocal Leukoencephalopathy (PML). In the trials included in this review, two cases of PML
were encountered: one in a patient who had received 29 doses of NTZ and a second fatal case of PML in another patient after 37 doses
of NTZ. Our protocol was insufficient to evaluate PML risk as well as other rare and long-term adverse events such as cancers and
other opportunistic infections, which are very important issues in considering the risk/benefit ratio of NTZ.
Authors’ conclusions
Although one trial did not contribute to efficacy results due to its duration, we found robust evidence in favour of a reduction in
relapses and disability at 2 years in RRMS patients treated with NTZ. The drug was well tolerated. There are current significant safety
concerns due to reporting of an increasing number of PML cases in patients treated with NTZ. This review was unable to provide an
up-to-date systematic assessment of the risk due to the maximum 2 year-duration of the trials included. An independent systematic
review of the safety profile of NTZ is warranted. NTZ should be used only by skilled neurologists in MS centres under surveillance
programs.
All the data in this review came from trials supported by the Pharmaceutical Industry. In agreement with the Cochrane Collaboration
policy, this may be considered a potential source of bias.
P L A I N L A N G U A G E S U M M A R Y
The use of the monoclonal antibody Natalizumab (NTZ) in patients with relapsing remitting multiple sclerosis (RRMS)
It is currently thought that inflammation is crucial in MS, leading to a disruption in the ability of nerves to conduct impulses. NTZ is
the first of a new generation of anti-inflammatory treatments forMS, which is given intravenously every 4 weeks. It is usually prescribed
once other drugs have failed or when the disease is rapidly worsening.
The Authors of this review evaluated the efficacy, tolerability and safety of NTZ in patients with RRMS. Among the pertinent literature,
3 studies met the inclusion criteria of methodological quality, comprising a total of 2223 participants. The results show that NTZ
treatment reduces the number of patients who experienced relapses and the number of patients who progressed at 2 years. AlsoMagnetic
Resonance scans show evidence of a beneficial effect of NTZ on disease activity.
Although information on adverse events (AEs) was limited, as most participants were followed up for 2 years only, infusion reactions,
anxiety, sinus congestion, lower limb swelling, rigors, vaginal inflammation and menstrual disorders were found to be more frequent
after NTZ treatment. However, the number of patients experiencing at least one AE (including severe or serious AEs) did not differ
between NTZ and control groups. On the contrary, significant safety concerns have been raised regarding Progressive Multifocal
Leukoencephalopathy (PML), a rare and often fatal viral disease characterized by damage to the white matter of the brain. In the studies
included in this review, PML was reported in 2 patients treated with NTZ for more than 2 years. However, our protocol was insufficient
to evaluate PML risk as well as other potential rare and long-term AEs (e.g. cancers and other infections) which are important issues in
considering the risk/benefit ratio of NTZ. An independent systematic review of the safety profile of NTZ is warranted. NTZ should
be used only by skilled neurologists in MS centres under surveillance programs.
All the data in this review came from studies supported by the Pharmaceutical Industry. In agreement with the Cochrane Collaboration
policy, this may be considered a potential source of bias.
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B A C K G R O U N D
Table 1 lists abbreviations used in the text.
Description of the condition
Multiple sclerosis (MS) is regarded as the foremost cause of non-
traumatic neurologic disability in young adults (Tremlett 2010).
MS is notoriously heterogeneous, both clinically and histopatho-
logically (Lucchinetti 1996), and characterised by unpredictability
from patient to patient and within a given individual over time.
In most cases it begins with episodic, largely reversible neurologic
dysfunction, in a pattern termed relapsing-remitting multiple scle-
rosis (RRMS) (Lublin 1996). Aminority of patients (ranging from
10 to 20% of cases) have benign MS (as defined by no or minimal
disability at 10 or 20 years), although this continues to be a con-
troversial issue (Pittock 2007). Natural history studies show that,
after about 10 years, about half of people with MS gradually de-
velop permanent disability, which may also include acute relapses;
this is known as secondary progressive MS (SPMS) (Weinshenker
1989). After amedian of 15-28 years (Weinshenker 1989;Tremlett
2006) from disease onset, a disability milestone equivalent to the
use of an assistive walking device is reached. There is an increased
risk of death in MS (Tremlett 2010).
Magnetic resonance imaging (MRI) does provide a reflection of
the underlying pathology, and it is integrated with clinical and
other paraclinical diagnostic methods to facilitate the diagnosis of
MS (McDonald 2001; Polman 2005). MRI parameters are used
as a surrogate marker of disease activity and/or progression. MRI
studies have shown that T2 lesion burden and contrast enhancing
lesions are representative of the active inflammatory component
which characterises the relapsing-remitting course, while their cor-
relation with disability is poor (Filippi 2002).
The disease has an adverse and often highly debilitating impact
on the quality of life (QoL) of people with MS and their families.
Relapses, even when they completely remit, are associated with a
level of temporary disability that disrupts working, family and so-
cial life. MS, even in its early stages, may undermine patients’ con-
fidence, restrict their activity and limit their role in society. Subtle
but disabling symptoms (such as fatigue, cognitive disturbances or
symptoms in the spectrum of anxiety and mood disorders), may
not be easily recognised and taken into consideration.
Although the etiology is largely unknown, it is believed that MS
develops in genetically predisposed individuals and that environ-
mental factors play a central role in its pathogenesis based on
immune-mediated mechanisms. It is thought that aberrant im-
mune responses to self or foreign antigens initiate and perpetuate
inflammation (Frohman 2006). The conventional hypothesis of
multiple sclerosis pathogenesis is that inflammation is the primary
event, leading to demyelination and subsequent axonal damage.
However, the role of inflammation is complex, with both benefi-
cial and deleterious features (Martino 2002). On the other hand,
some researchers hypothesise that inflammation is not the primary
pathogenic mechanism, that axonal loss occurs early and that a
cryptic aetiological agent may cause axonal damage and demyeli-
nation, as well as inducing an inflammatory response, which plays
a secondary role (Trapp 1998; Maggs 2004).
In summary the current predominant school of thought is that
the acute inflammatory process characterises the initial stage of
the illness, while progression of disability is more closely related
to irreversible damage to myelin and axons. These features have
important implications for therapy: strategies that target inflam-
mation will only have a limited influence on progression once pa-
tients have entered the progressive phase of the disease.
Description of the intervention
Natalizumab (NTZ) (Tysabri®, previously labelled Antegren®;
Elan Pharmaceuticals Inc., San Diego, CA, and Biogen Idec Inc.,
Cambridge, MA) is a recombinant humanized monoclonal anti-
body. It contains human IgG4 framework regions and the com-
plementary-determining regions of a murine antibody that binds
to the α4 chain of α4β1 integrin. The murine region may re-
sult in the generation of neutralizing antibodies or allergic reac-
tions. The human region endows natalizumab with the effector
functions of immunoglobulin subclass IgG4, which is the least
immune activating amongst the human IgGs. The recommended
dose of Tysabri® is 300 mg intravenous (IV) infusion every four
weeks (FDA 2004).
Tysabri® was approved by Food and Drug Administration (FDA)
for treatment of patients with RRMS on 23 November 2004 after
priority review of 1-year data from the two ongoing SENTINEL
and AFFIRM trials. Priority review and accelerated approval was
determined to be appropriate because of the strength of the effi-
cacy and safety data available at 1 year. Following the recognition
of two cases of progressive multifocal leukoencephalopathy (PML)
in patients who had been receiving NTZ, Biogen Idec and Elan
Pharmaceuticals, in discussions with the FDA, suspended com-
mercialization and clinical trials on 28 February 2005 and started
to investigate the relationship between PML and NTZ therapy.
A comprehensive clinical, radiological, and laboratory investiga-
tion of patients exposed to NTZ in clinical trials (including trials
carried on in patients with Crohn Disease - CD) was completed
(Yousry 2006). In addition, the 2-year results of SENTINEL and
AFFIRM trials were submitted to the FDA in September 2005.
On July 2006 marketing of Tysabri® resumed . In the following
months, Tysabri® was gradually commercialised worldwide.
How the intervention might work
Inflammatory lesions in MS appear to arise after activated leuco-
cytes gain access to the CNS from the circulation. Integrins on the
surface of leucocytes interact with immunoglobulin superfamily
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proteins on cerebral endothelial cells, facilitating diapedesis across
the blood-brain barrier. Examples of integrin / immunoglobulin
superfamily pairs are VLA4/VCAM1 and LFA1/ICAM1. NTZ is
a monoclonal antibody against α4-integrin (part of VLA4), thus
preventing interaction of VLA4- with VCAM1 and, as a con-
sequence, blocking the transmigration of VLA4-expressing leu-
cocytes across the blood-brain barrier (Niino 2006; Ransohoff
2007). In preclinical studies, NTZ reduced disease activity in mice
with experimentally induced allergic encephalomyelitis, an animal
model of MS (Yednock 1992; Kent 1995).
Why it is important to do this review
Tysabri® is available in many countries for treating RRMS. As a
result of the risk of PML (Yousry 2006), it is generally recom-
mended as second-line therapy in RRMS if a conventional DMD
has failed, and in rapidly evolving severe disease (e.g. FDA 2006,
EMA 2009, AIFA 2006, NICE 2007). The details of the eligi-
bility criteria vary from country to country. A systematic review
to assess the efficacy and side effect profile of NTZ is timely and
important.
O B J E C T I V E S
The efficacy, tolerability and safety of NTZ in the treatment of
people with RRMS were evaluated.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Double-blind, randomised, controlled trials (RCTs). Trials were
not excluded on the basis of duration of treatment (except those
involving a single infusion) or length of follow up.
Types of participants
Patients with RRMS of both gender who met the criteria of Poser
(Poser 1983) for clinically definite or laboratory-supported definite
MS, or the original / revisedMcDonald criteria (McDonald 2001,
Polman 2005), aged > 17 years.
Types of interventions
NTZ (dosage > 3 mg/Kg IV infusion every 4 weeks), also as add-
on treatment, versus placebo or other drug.
Types of outcome measures
Primary outcomes
We assessed the following primary outcome measures:
(1) The number of patients experiencing at least one relapse at
2 years. Definitions of relapse given in the original studies were
accepted.
(2) The number of patients who progressed at 2 years. Defini-
tions of progression given in the original studies were accepted.
However, we tried to evaluate this outcome using the definition
of progression as a persistent worsening of at least one point in
EDSS (Kurtzke 1983), recorded outside a relapse and confirmed
by a follow-up assessment at six months; a persistent half-point
increase was adopted if baseline EDSS was 5.5 or worse.
(3) Mean change in Short Form 36 (SF-36) scores (Ware 1992)
at 2 years. The SF-36 is a widely used, generic measure of self-
reported health status that consists of 35 items investigating eight
domains over the previousmonth: physical functioning (10 items),
social functioning (2 items), physical role limitations (4 items),
mental health (5 items), emotional role limitations (3 items), pain
(2 items), energy/vitality (4 items), and general health (5 items);
one more item (change in health over the previous year) was not
used in scoring. Higher scores indicate higher QoL. The scores
for the eight domains can be reduced to two composite scores, the
Physical Component Summary (PCS) and the Mental Compo-
nent Summary (MCS), by means of principal component analysis
(Ware 1993). These summary scales are computed as standardized
scores such that a mean score of 50 (standard deviation [SD], 10)
corresponds to that of the general US population.
(4) The number of patients with at least one severe AE during 2
years of treatment. Many terms are used to describe harm associ-
ated with healthcare interventions, causing confusion. Thus, we
define an “adverse event” as any unfavourable outcome that occurs
during or after the study, whether or not related to the study drug,
including an exacerbation of a preexisting condition, except for
MS progression; we also include hospitalization or death (what-
ever the cause of both). With respect to their severity, definition
of severe AE given in the original studies was accepted. If not oth-
erwise specified, AEs were defined as severe when leading to with-
drawal from the study or discontinuation of treatment without
satisfying the definition of serious AE (see below for definition).
It may be helpful to remember that the term “severe” refers to the
intensity of a particular AE and is not synonymous with “serious”,
i.e. it refers to tolerability, while “serious” (see below for definition)
refers to safety (e.g. a non-serious AE, such as headache, may be
severe in intensity as opposed to mild or moderate) (ICH Expert
Working Group 1994).
(5) The number of patients with a serious AE (no period restric-
tion). Definitions of serious AE were those reported by the Expert
Working Group of the International Conference on Harmonisa-
tion of Technical Requirements for Registration of Pharmaceuti-
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cals for Human Use (ICH) (death, life-threatening event, hospi-
talisation or prolongation of existing hospitalisation, persistent or
significant disability) (ICH Expert Working Group 1994), except
for the fact that we did not consider permanent or significant dis-
ability caused by MS as a serious AE.
Secondary outcomes
The secondary outcome measures included:
(1) Time to progression of disability at 2 years
(2) Mean change in EDSS score at 2 years
(3) Mean change in Multiple Sclerosis Functional Composite
(MSFC - Rudick 2002) at 2 years
(4) The number of patients who were unable to walk without aid
(EDSS greater than 5.5) at 2 years
(5) Mean change in Modified Fatigue Impact Scale (MFIS) at 2
years (Kos 2005)
(6)Mean change in well-being as measured by a visual analog scale
(VAS) at 2 years
(7) Mean change in PASAT (one of the components of MSFC),
which assess cognitive function, at 2 years (Gronwall 1977)
(8) The number of patients experiencing clinically significant
worsening of vision at 2 years [defined as two-line (10-letter) re-
ductions in Sloan chart scores, sustained over 12 weeks] (Balcer
2000; Rosser 2003)
(9) The number of patients who showed at least one gadolinium-
enhancing lesion at 2 years
(10) The mean change of total lesion load on T2-weighted images
at 2 years
(11) The number of patients experiencing at least one AE, no
matterwhethermild or severe, serious or not (noperiod restriction)
(12) The number of patients experiencing treatment discontinu-
ation caused by AE
(13) The number of patients experiencing a relapse in the 4 weeks
after the first dose of NTZ
Search methods for identification of studies
A systematic search without language restrictions was conducted
to identify all relevant published and unpublished randomised
controlled trials.
For additional information about theGroup’s search strategy please
see: Cochrane Multiple Sclerosis Group
Electronic searches
We searched the following databases
1. Cochrane Multiple Sclerosis Group Trials Register (19
February 2010)
2. The Cochrane Central Register of Controlled Trials
(CENTRAL) “The Cochrane Library”(Issue 1, 2010) (Appendix
1)
3. MEDLINE (PubMed) (1966 to 19 February 2010)
(Appendix 2)
4. EMBASE (EMBASE.com) (1988 to 19 February 2010)
(Appendix 3)
Searching other resources
Handsearching of the references quoted or linked to the identified
trials and other papers of interest, congress reports (1998 to Febru-
ary 2010) of the American Academy of Neurology, the American
Neurological Association, the AmericanCommittee for Treatment
and Research in MS, the European Committee for Treatment and
Research inMS and the Italian Neurological Society. Contact with
researchers who were participating in trials on NTZ; and contact
with Biogen or other pharmaceutical companies.
In additionwe checked the following sources for trials aboutNTZ:
clinicaltrials.gov (www.clinicaltrials.gov); US Food and Drug Ad-
ministration (FDA) (www.fda.gov), the European Public Assess-
ment Reports from the European Medicines Evaluation Agency
(EMA) (www.emea.eu) and the National Institute for health and
Clinical Excellence (NICE) (www.nice.org.uk).
Data collection and analysis
Selection of studies
Three reviewers (EP, GG, AS - all MS experts), independently as-
sessed the eligibility of articles for the review. The same review-
ers independently scrutinised the full texts of the selected studies
and decided which trials met the inclusion criteria. All reviewers
assessing the relevance of studies knew the names of the authors,
institutions, journal of publication and results when they applied
the eligibility criteria. Any disagreement was resolved by discus-
sion.
Data extraction and management
Two reviewers (EP, IG) extracted the data independently: char-
acteristics of participants, interventions, duration of treatment,
length of follow-up, outcome measures, side effects and adverse
events. We sought to extract from each RCT the number of pa-
tients originally assigned to each treatment group to allow an in-
tention-to-treat analysis, if the trial was not already presented in
this way. Disagreement was resolved by discussion amongst all the
reviewers. All data was registered on a collection form. Study au-
thors were consulted to resolve controversies and clarify questions,
including missing data, which were posed by the two reviewers ex-
tracting data. Similar clarifications were sought with Biogen Idec
Inc. and Elan Pharmaceuticals Inc, through theMedical Direction
of Biogen-Dompè Italy.
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Assessment of risk of bias in included studies
The risk of bias assessment for RCTs and CCTs was performed as
recommended by the Cochrane Handbook (Handbook 5 2008)
using a two-part tool addressing seven specific domains: sequence
generation and allocation concealment (selection bias), blinding
of participants and providers (performance bias), blinding of out-
come assessor (detection bias), incomplete outcome data (attri-
tion bias), selective outcome reporting (reporting bias) and other
sources of bias. The first part of the tool involves describing what
was reported to have happened in the study. The second part of
the tool involves assigning a judgement relating to the risk of bias
for that entry, in terms of low, high or unclear risk. See Appendix
4 for details.
The domains of sequence generation, allocation concealment
(avoidance of selection bias) and selective outcome reporting
(avoidance of reporting bias) were addressed in the tool by a single
entry for each study.
Blinding of participants, personnel and outcome assessor (avoid-
ance of performance bias and detection bias) were considered sep-
arately for both objective and subjective outcomes.
We assessed whether included studies were in line with the CON-
SORT Statement (Moher 2001), a reflection of the risk for biased
estimates of treatment effects (Schulz 1995;Moher 1998).Despite
the controversy surrounding the importance of the CONSORT
Statement (see “‘Risk of bias’ and ‘quality’” in Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2008), we
felt that adherence to such a statement that aims to improve trial
reporting was appropriate.
Measures of treatment effect
Datawas analysed according to an intention-to-treat approach.We
analysed dichotomous outcomes by calculating relative risks (RR)
for each trial with the uncertainty in each trial being expressed
using 95% confidence intervals (95% CI). Difference in means
(MD) across trials was used for continuous outcomes.
If not available, standard deviations were obtained from sample
size, mean values and p-values.
Where appropriate, we planned to calculate Number Needed to
Treat (NNT), i.e. Number Needed to Benefit (NNB) or Number
Needed toHarm (NNH), as follows:NNT=1/[BR(1- RR)], where
BR is the baseline risk (rate of the event in the control group) and
RR is the relative risk resulting from meta analysis.
Assessment of heterogeneity
The statistic I2 was calculated for each pooled estimate, in order
to assess the impact of statistical heterogeneity. I2 may be inter-
preted as the proportion of total variation among effect estimates
that is due to heterogeneity rather than sampling error, and it is
intrinsically independent of the number of studies. When I2 <
30% there is little concern about statistical heterogeneity Higgins
2002;Higgins 2003).Weused the random-effectmodel to take ac-
count of the between-study variance in our findings (DerSimonian
1986). A sensitivity analysis was performed if I2 was 30% or more,
comparing results obtained via random- and fixed-effect models.
Data synthesis
We used Review Manager (RevMan) 2008 to perform meta-anal-
yses of the included studies and displayed the results as forest plots.
Descriptive analyses of included and excluded trials were also un-
dertaken.
Subgroup analysis and investigation of heterogeneity
Subgroup analysiswere planned for analysingparticular AEswhich
were pooled with other AEs in a generic label. For example, serious
AEs due toMS relapse were analysed separately from other serious
AEs.
Possible sources of heterogeneity were explored by subgroup anal-
ysis where appropriate.
Sensitivity analysis
In order to incorporate assessment of risk of bias in the review
process we planned to plot intervention effects estimates stratified
for risk of bias for each relevant domain. In case of differences
in results among studies with different risks of bias, we planned
to perform sensitivity analysis excluding studies with high risk of
bias.
Many issues suitable for sensitivity analysis are only identified dur-
ing the review process where the individual peculiarities of the
studies under investigation are identified. Thus, we retained the
opportunity to carry out other sensitivity analyses during the re-
view process that could affect the overall result and conclusions.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
After eliminating duplicates, the number of hits retrieved by the
Cochrane Multiple Sclerosis Group systematic search strategy was
251. Eleven articles were considered as potentially eligible after
screening of titles and abstracts, with consensus among the review-
ers. After study of the full text, with consensus among the review-
ers,10 were confirmed as potentially relevant papers. The article
excluded concerned the UK Antegren Study 1999.
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No further studies were identified by handsearching of congress
reports and other sources.
At this point, the process of linking multiple reports of the same
study was carried out. Four studies were identified. Three iden-
tified studies completely satisfied the criteria for inclusion in this
review. The fourth study, the INMSTG trial (INMSTG 2003),
included participants affected with both RRMS and SPMS, who
were randomised to two different doses of NTZ (3 or 6 mg per
kilogram) or placebo. We contacted the study investigators in or-
der to obtain data onRRMS patients in the placebo arm and in the
6 mg per kilogram arm. The INMSTG trial did not contribute to
the metanalysis because we did not receive any data from the in-
vestigators; for this reason it was included in “studies awaiting clas-
sification” (see Characteristics of studies awaiting classification).
Included studies
Three studies met the inclusion criteria: one placebo-controlled
trial (942 patients) (AFFIRM 2006) and two add-on placebo-
controlled trials, i.e. one plus glatiramer acetate (110 patients)
(GLANCE 2009) and the second plus interferon beta-1a (1171
patients) (SENTINEL 2006).
For details see “Characteristics of included studies”. Baseline char-
acteristics of participants in the studies which contributed to pri-
mary efficacy outcomes are summarised in Table 2.
Excluded studies
See “Characteristics of excluded studies”.
Risk of bias in included studies
Figure 1 shows authors’ judgements on each methodological qual-
ity item presented as percentages across all included studies.
Figure 1. Methodological quality graph: review authors’ judgements on each methodological quality item
presented as percentages across all included studies.
Figure 2 shows authors’ judgements on each methodological qual-
ity item for each included study.
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Figure 2. Methodological quality summary: review authors’ judgements on each methodological quality
item for each included study.
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All the data of the present review came from trials supported by
Biogen Idec and Elan Pharmaceuticals. All primary references of
the included RCTs reported author financial disclosures. Author-
industry ties were reported for 100% of the authors of the primary
reference for each trial. In particular, 4 out of the 14 authors
(AFFIRM 2006), 4 out of the 12 authors (GLANCE 2009) and
3 out of the 12 authors (SENTINEL 2006) were employees of
Biogen Idec.
Since one of the included trials (SENTINEL 2006), which con-
tributed to primary efficacy outcomes, was an add on study, in
which the control arm was placebo plus interferon beta 1a (IFNß-
1a), one possible risk was underestimation or overestimation of the
effect size of NTZ efficacy due to interaction between the DMDs.
Results for the NTZ group versus placebo were also reported sep-
arately. The use of GA or IFNß-1a in two of the included trials
may have biased safety/tolerability outcomes because of interac-
tions between these DMDs and NTZ.
The different durations of included trials could have been a source
of bias with respect to secondary safety/tolerability outcomes. To
address this concern we performed a sensitivity analysis comparing
results including and excluding GLANCE 2009 for tolerability/
safety outcomes, given the short period of follow-up (6 months)
in this trial.
Protocol violations may affect results by introducing bias. Data
about protocol violations are reported in Table 3, Table 4 and
Table 5, and are mainly derived from the FDA’s CDER “medical
review” (FDA 2004). Unfortunately, the CDER only analysed 1-
year data from the SENTINEL 2006 and AFFIRM 2006 trials. As
far as this 1-year analysis is concerned, the frequency of protocol
violations was considered similar for the two treatment arms in
both trials.
Allocation
The AFFIRM 2006 and the SENTINEL 2006 studies had ade-
quate sequence generation and allocation concealment. Randomi-
sation was carried out with the use of a computer-generated sched-
ule and amultidigit identification number, implemented byway of
an interactive voice-response system. There was insufficient pub-
lished information about the method of randomisation and treat-
ment allocation of the GLANCE 2009 trial.
Blinding
All the included studies were double-blinded.
The occurrence of more frequent AEs in NTZ treated subjects
(such as headache during infusion) was not of sufficiently large
size to raise concerns about blinding.
A well-established pharmacodynamic feature of NTZ is the in-
crease in number of all circulating leukocytes except neutrophils
(Polman 2006 - AFFIRM 2006). The increase of leukocytes was
appropriately taken in consideration in blinding procedures, at
least in the AFFIRM 2006 and SENTINEL 2006 trials (see be-
low).
Adequacy of double-blinding was appropriate in AFFIRM 2006
and SENTINEL 2006 studies. At each study site, primary and
backup examining neurologists (who were not in contact with
patients in any other capacity including laboratory assessments)
and primary and backup treating neurologists were designated.
However, to our knowledge no analyses of the efficacy of blinding
was carried out in the included studies.
Incomplete outcome data
All included studies: (a) reported the percentage of patients who
dropped out from the study for each assignment group; (b) re-
ported the percentage of patients who discontinued the treatment
but continued follow up (including CONSORT flowcharts); (c)
performed the analysis according to the intention-to-treat princi-
ple. However, none of the papers described how missing data was
imputed for ITT analysis of primary outcomes (the rate of clinical
relapse at one year and the rate of sustained progression of disabil-
ity, as measured by the EDSS, at 2 years). Considering secondary
outcomes, the AFFIRM 2006 and SENTINEL 2006 papers re-
ported that missing values were imputed using the mean for the
respective measures in the study population. ITT statements with
no further details carry a risk of bias. Thus, after resolution of
controversy among EP and SM, the methodological quality item
“incomplete outcome data addressed” was judged as unclear.
It was not possible to carry out sensitivity analysis to assess the
effect of patients who withdrew since raw data was not available
to enable an “available case analysis”. Data on “the number of pa-
tients experiencing at least one relapse” was extracted from Table
2 in Polman 2006 (AFFIRM 2006) and from Table 2 in Rudick
2006 (SENTINEL 2006). In both the tables, looking at the item
“Number of relapses - no. of patients”, one can see that the total
number of patients in each arm is equal to the number of ran-
domised patients (ITT populations), but it is not specified how
missing values were included. As far as “the number of patients
who progressed” is concerned, data was obtained from theKaplan-
Meier plots in Figure 2 in Polman 2006 (AFFIRM 2006) and in
Figure 2 in Rudick 2006 (SENTINEL 2006).
The percentages of patients who withdrew were low, and similar,
between NTZ treated and untreated patients, and the reasons for
withdrawal were comparable.
In the AFFIRM trial, the discrepancy between the number of ran-
domised patients (n=315) and the number of patients submitted
to safety analysis (n=312) is due to the fact that three patients who
were assigned to receive placebo were never treated; these patients
were included in the ITT efficacy analyses but were excluded from
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the safety analyses.
MRI data was not available for 8 to 9% of patients at year 2 in the
AFFIRMtrial (Miller 2007 - AFFIRM 2006). Themain reason for
missing data (>80%)was the scan not being performed because the
patient withdrew from the study; in the remainder, although the
patient remained in the study, the scan was either not performed,
had not been received at the Central MRI Analysis Center, or had
been received but was of inadequate quality for analysis (Miller
2007 - AFFIRM 2006).
The SENTINEL2006 trial was stopped approximately onemonth
early because of 2 reports of PML.
In the SENTINEL 2006 trial 25 patients were excluded from
analysis because of irregularities in data (the original enrolled co-
hort was of 1196 patients while 1171 patients were included in
ITT analysis). We did not analyse the effect of this exclusion but
the FDA Center for drug evaluation and research (CDER) did,
through a “worst case” sensitivity analyses. That analysis did not
bring to light significant effects on overall study results at 1 year
(FDA 2004a).
Selective reporting
We did not identify any selective reporting in all the included
studies.
Other potential sources of bias
We did not find any other study characteristics that may have
negatively affected the quality of the trials. Except for GLANCE
2009, papers reported that the studies were overseen by indepen-
dent data and safety monitoring committees; sample size calcula-
tion was performed in all included trials.
Due to the limited number of trials available, we did not perform
additional subgroup analyses.
Effects of interventions
PRIMARY EFFICACY OUTCOME MEASURES
(1)THENUMBEROFPARTICIPANTSEXPERIENCINGAT
LEASTONERELAPSEDURING2YEARSOFTREATMENT
Data was available from the AFFIRM (Polman 2006, AFFIRM
2006) and SENTINEL (Rudick 2006, SENTINEL 2006) trials
for a total of 2113 participants. Relapses were defined as new or
recurrent neurologic symptoms not associated with fever or infec-
tion, lasting at least 24 hours, and accompanied by new, objective
neurologic findings.
The pooled estimate was RR=0.57 (95% CI 0.47 to 0.69), show-
ing statistical evidence in favour of NTZ. This result can be re-
expressed as follows: NTZ (with or without IFNß-1a) reduced the
risk of experiencing at least one new exacerbation at 2 years by
30% to 50% as compared to not receiving NTZ.
In order to avoid one patient from experiencing at least one relapse
during two years of treatment, 3 to 5 people would have to receive
NTZ (NNB=4, 95% CI 3 to 5).
There was heterogeneity between the trials (I2=71%), but no dif-
ference was found between fixed- and random-effect models.
(2) THE NUMBER OF PATIENTS WHO PROGRESSED AT
2 YEARS
Data was available from the AFFIRM (Polman 2006, AFFIRM
2006) and SENTINEL (Rudick 2006, SENTINEL 2006) trials
for a total of 2113 participants. Definitions of progression given in
the original studieswere used: in both studies sustainedprogression
of disability was defined as an EDSS increase of 1.0 or more from
a baseline score of 1.0 or more, or an EDSS increase of 1.5 or
more from a baseline score of 0 that was sustained for 12 weeks
(progression could not be confirmed during a relapse).
The pooled estimatewasRR=0.74 (95%CI0.62 to 0.89), showing
statistical evidence of efficacy of NTZ in reducing the number of
patients who progressed. In other words, NTZ (with or without
IFNß-1a) reduced the risk of experiencing progression at 2 years
by 10% to 40% as compared to a control group not receiving
NTZ.
The number of patients needing treatment with NTZ in order to
avoid progression in one patient at 2 years is 10 (NNB=10, 95%
CI 7 to 23).
There was heterogeneity between the trials (I2=52%), but this was
not confirmed in the sensitivity analysis (data not shown).
(3) MEAN CHANGE IN SF-36 SCALE SCORES AT 2 YEARS
The PCS and the MCS were analysed separately. Data was avail-
able from the AFFIRM and SENTINEL trials (Rudick 2007,
SENTINEL 2006, AFFIRM 2006) for a total of 2113 patients.
The mean difference in PCS mean change between the NTZ and
control groups favoured NTZ treated patients (MD=1.98, 95%
CI 1.05 to 2.91, p<0.0001). There was no statistical evidence of
heterogeneity (I2=0).
The mean difference in MCS mean change between NTZ and
control groups showed adifference favouringNTZ treated patients
(MD=1.38, 95%CI0.33 to 2.42, p=0.01). Therewas no statistical
evidence of heterogeneity (I2=0).
SECONDARY EFFICACY OUTCOME MEASURES
The following measures were planned as secondary efficacy out-
come measures in the protocol:
(1) TIME TO PROGRESSION IN DISABILITY AT 2 YEARS
No data was available despite contacting authors and sponsor.
(2) MEAN CHANGE IN EDSS SCORE AT 2 YEARS
No data was available despite contacting authors and sponsor.
(3) MEAN CHANGE IN MSFC AT 2 YEARS
No data was available despite contacting authors and sponsor.
(4) THE NUMBER OF PATIENTS WHO WERE UNABLE
TOWALK WITHOUT AID (EDSS > 5.5) AT 2 YEARS
No data was available despite contacting authors and sponsor.
(5) MEAN CHANGE IN MFIS AT 2 YEARS
No data was available despite contacting authors and sponsor.
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(6) MEAN CHANGE IN WELL-BEING AS MEASURED BY
A VAS AT 2 YEARS
Data was only available from the AFFIRM trial (Rudick 2007,
AFFIRM 2006) for a total of 942 patients.
Mean difference betweenNTZ and control groups favoured NTZ
treatment (MD=6.40, 95% CI 1.76 to 11.04, p= 0.007).
(7) MEAN CHANGE IN PASAT AT 2 YEARS
No data was available despite contacting authors and sponsor.
(8) THE NUMBER OF PATIENTS EXPERIENCING CLIN-
ICALLY SIGNIFICANT WORSENING OF VISION AT 2
YEARS
Clinically significant worsening of vision was defined as two-line
(10-letter) reductions in Sloan chart scores, sustained over 12
weeks (Balcer 2000, Rosser 2003). Data from AFFIRM and SEN-
TINEL trials was published in Balcer 2007 (SENTINEL 2006
AFFIRM 2006) but it could not be extracted in a form suitable
for the meta-analysis. Data was requested from the authors and
sponsor, but no response was received.
(9) THE NUMBER OF PATIENTS WHO SHOWED AT
LEAST ONE GADOLINIUM-ENHANCING LESION AT 2
YEARS
Data was available from the AFFIRM (Polman 2006, AFFIRM
2006) and the SENTINEL (Rudick 2006, SENTINEL 2006)
trials for a total of 2113 participants.
The number of patients with at least one Gadolinium-enhancing
lesion was lower in the NTZ group as compared to the control
group (RR=0.12, 95% CI 0.09 to 0.17). In other words, NTZ
(with or without IFNß-1a) reduces the risk of developing at least
one Gadolinium-enhancing lesion at 2 years by 87%. NNB is 4
(95%CI 4 to 4). There was no statistical evidence of heterogeneity
(I2=0).
(10) THE MEAN CHANGE OF TOTAL LESION LOAD ON
T2-WEIGHTED IMAGES AT 2 YEARS
Data was available from the AFFIRM trial (Miller 2007, AFFIRM
2006) for 855 patients (91% from a total of 942). Over 2 years,
NTZ significantly reduced the mean change in T2 lesion volume
compared with placebo (MD = -3796, 95% CI -5849.43 to -
1742.97, p = 0.0003).
PRIMARY SAFETY OUTCOMES
(1) THE NUMBER OF PATIENTS WITH SEVERE AE AT 2
YEARS
Herewe report the numbers of patientswith a severeAE as reported
in the original papers from 2110 RRMS patients over two years
[Polman 2006, (AFFIRM 2006) and Rudick 2006, (SENTINEL
2006)]. Number of patients experiencing at least one severe AE
did not differ between patients treated with NTZ and controls
RR=0.92 (95% CI 0.81 to 1.04), with no statistical evidence of
heterogeneity (I2=0%).
(2) THE NUMBER OF PATIENTS WITH SERIOUS AE
Serious AE were collected from SENTINEL (Rudick 2006,
SENTINEL 2006), AFFIRM (Polman 2006, AFFIRM2006) and
GLANCE (Goodman 2009, GLANCE 2009) trials.
Pooled estimate showed that serious AEs in the NTZ group (227/
1271, or 18%) were less common than in the control group (199/
949, or 21%): RR=0.83 (95% CI 0.70 to 0.98). No statistical
evidence of heterogeneity was found (I2=0%). Since serious AEs
prevailed in the control group. NNH was not calculated.
A sensitivity analysis excluding theGLANCE trial whichwas char-
acterised by lower occurrence of serious AEs (2% in the NTZ arm
and 4% in the control arm over 6 months, vs. 18% and 21%
[SENTINEL 2006] and 19% and 24% [AFFIRM 2006], respec-
tively, over 2 years) did not change findings: RR=0.83 (95% CI
0.70 to 0.99).
Two cases of PMLwere included in the serious AEs. Theywere two
participants in the SENTINEL trial who were diagnosed as having
PML after their completion of the two-year study (after 29 and 37
doses of NTZ respectively) (Langer-Gould 2005; Kleinschmidt-
DeMasters 2005).
The most common serious AE was a relapse of MS, which was sig-
nificantly more frequent in controls than in NTZ-treated patients
(RR= 0.50, 95%CI 0.37 to 0.68). We speculated thatMS relapses
were considered as serious AEs because they resulted in hospitali-
sation (unofficial communication from the Medical Direction of
Biogen-Dompé Italia in May 2009). When recalculating serious
AEs without including MS relapses, we did not find any statistical
difference between NTZ and control groups (RR=1.13, 95% CI
0.90 to 1.43).
Death occurred in 3 patients in the SENTINEL trial: 2 were
assigned to IFNß-1a alone and one was the fatal case of PML after
37 doses of NTZ (Kleinschmidt-DeMasters 2005). Two deaths
occurred in the AFFIRM study, both in the NTZ group. One
patient died of malignant melanoma. A second patient, a 49 year-
old woman, died of alcohol intoxication (Polman 2006, AFFIRM
2006) (a suicide was suspected - unofficial communication from
the Medical Direction of Biogen-Dompé Italia in May 2009).
SECONDARY SAFETY OUTCOMES
We assessed the following secondary safety outcome measures at
any time of follow-up:
(1) THE NUMBER OF PATIENTS EXPERIENCING AT
LEAST ONE AE
In SENTINEL (Rudick 2006, SENTINEL 2006), AFFIRM (Pol-
man 2006, AFFIRM 2006) and GLANCE (Goodman 2009,
GLANCE 2009) trials, the numbers of patients who reported at
least one AE were given.
Number of patients experiencing at least one AE did not differ
between patients treated with NTZ and controls [RR=1.00 (95%
CI 0.99 to 1.01)], with no statistical evidence of heterogeneity (I
2=0%).
As far as the type of AE is concerned, we report those AE which
were significantly different between NTZ-treated and placebo-
treated patients, as follows:
• In the SENTINEL study, anxiety was statistically more
frequent in patients treated with NTZ than in patients who were
not (RR=1.49, 95% CI 1.05 to 2.12). Data on anxiety was not
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reported in the AFFIRM and GLANCE papers.
• In the SENTINEL study, “sinus congestion” was
statistically more frequent in patients treated with NTZ than in
patients who were not (RR=2.03, 95% CI 1.15 to 3.59). In the
AFFIRM and GLANCE studies, the term “sinus congestion” was
not reported among the AEs.
• In the SENTINEL study, “peripheral edema” was
statistically more frequent in patients treated with NTZ than in
patients who were not (RR=4.78, 95% CI 2.00 to 11.42). In the
AFFIRM and GLANCE papers, the authors did not report the
term “peripheral edema” among the AEs.
• “Rigors” were statistically more frequent in patients treated
with NTZ than in patients who were not (RR=3.54, 95% CI
1.16 to 10.83). In the SENTINEL trial (Rudick 2006,
SENTINEL 2006) the term “rigors” was not mentioned among
the AEs.
• In the AFFIRM study, “vaginitis” was statistically more
frequent in women treated with NTZ than in those who were
not (RR=1.65, 95% CI 1.01 to 2.71). In the SENTINEL
(Rudick 2006, SENTINEL 2006) and GLANCE (Goodman
2009, GLANCE 2009) studies the term “vaginitis” was not
reported among the AEs.
• In the AFFIRM study, menstrual disorders were statistically
more frequent in women treated with natalizumab than in those
who were treated with placebo (RR=1.89, 95% CI 1.09 to 3.29).
In the SENTINEL (Rudick 2006, SENTINEL 2006) and
GLANCE (Goodman 2009, GLANCE 2009) trials menstrual
disorders were not reported among the AEs.
• In the SENTINEL, AFFIRM and GLANCE trials, the
numbers of patients who suffered from “infusion reactions“ and
“hypersensitivity reactions” (HSRs) were reported. “Infusion
reactions” were defined as any event that occurred within two
hours after the start of the infusion. “Infusion reactions” were
more frequent in NTZ-treated patients than in controls (RR=
1.24, 95% CI 1.05 to 1.47). The most common “infusion
reaction” was headache. However, when only headache was
analysed, no statistical significant difference was found between
NTZ-treated participants and controls. HSRs, which are a major
concern among clinicians, were more frequent in NTZ-treated
patients than in controls but this was not statistically significant
(RR=3.43, 95% CI 0.33 to 36.07). The term “HSRs” included
all conditions defined as “hypersensitivity”, “allergic reaction”,
“anaphylactic/anaphylactoid reaction”, “urticaria”, “allergic
dermatitis”, or “hives”. There was, however, heterogeneity
among the trials (I2=65%), and when repeating the comparison
with the fixed model, a statistically significant difference was
found. Since the most likely source of heterogeneity was the
GLANCE trial, the comparison was repeated without the
GLANCE data. In this comparison, HSRs were significantly
more frequent in NTZ-treated patients without evidence of
heterogeneity (I2 <30% using either the random-effect or fixed-
effect methods). No cardiovascular or respiratory compromise
was associated with any of these events classified as HSRs, except
for one patient who received epinephrine and one patient who
required supplemental oxygen (both in the AFFIRM 2006 trial,
Polman 2006, Phillips 2006). In the AFFIRM study two NTZ
patients were re-dosed after experiencing a hypersensitivity
reaction (protocol violation); thus, a total of 27 HSRs were
observed in 25 NTZ patients (Phillips 2006, AFFIRM 2006).
Since clinically significant liver injury has been reported in pa-
tients treated with NTZ in the post-marketing setting (Francis
2008, US FDA 2008), we looked at liver-function tests. The num-
ber of patients experiencing an abnormality in liver-function tests
was only available in the AFFIRM study (Polman 2006, AFFIRM
2006), without evidence of statistically significant differences be-
tweenNTZ and placebo groups (RR=1.29, 95%CI 0.67 to 2.47).
In the SENTINEL study (Rudick 2006, SENTINEL 2006) it is
stated that “no increase in the incidence of chemical abnormali-
ties, including the results of liver-function tests, was observed with
combination therapy”; the same applies for the GLANCE trial
(Goodman 2009, GLANCE 2009).
Finally, we pooled data regarding the number of patients with at
least one “infection” (irrespective of infection type) and found no
evidence of differences between NTZ and placebo groups (RR=
1.01, 95% CI 0.97 to 1.06; I2=0%).
(2) THENUMBEROF PATIENTS EXPERIENCINGTREAT-
MENT DISCONTINUATION CAUSED BY AE
Datawas available for the SENTINEL (Rudick 2006, SENTINEL
2006), AFFIRM (Polman 2006, AFFIRM 2006) and GLANCE
(Goodman 2009,GLANCE 2009) trials. The pooled estimate was
RR= 1.14 (95%CI 0.82 to 1.59), showing no statistical difference
in the rate of discontinuation between patients who took NTZ
and those who did not; there was no statistical evidence of hetero-
geneity (I2=0%). It is important to mention that we encountered
difficulty in extracting raw data for this outcome; differences be-
tween the review authors were resolved by discussion.
(3) THE NUMBER OF PATIENTS EXPERIENCING A RE-
LAPSE IN THE 4 WEEKS AFTER THE FIRST DOSE OF
NTZ
No data was available despite contacting the authors and sponsor.
D I S C U S S I O N
Summary of main results
Our results show statistical evidence in favour of NTZ for all
the primary efficacy outcome measures and for those secondary
efficacy measures for which data was available.
NTZ (with or without IFNß-1a once a week) reduced the risk of
experiencing at least one new exacerbation at 2 years by about 40%
and the risk of experiencing progression at 2 years by about 25%
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as compared to a control group. To reduce the risk of experiencing
at least one new exacerbation, 3 to 5 patients need to receive NTZ
(with or without IFNß-1a once a week) (NNB=4; 95% CI 3 to
5). The number of patients needing treatment with NTZ in order
to prevent progression in one patient at 2 years is 7 to 23 (NNB=
10; 95% CI 7 to 23). It is noteworthy that the effect size is high
for both primary outcomes, with NNB of 4 and 10. Confidence
intervals show that the estimate is very precise for the risk of at
least one new exacerbation, though less so for progression.
NTZ therapy results in significant HRQoL benefits. Both PCS
and MCS mean changes favour NTZ-treated patients.
Available data was not suitable for metanalysis of the following
secondary efficacy outcome measures: time to progression at 2
years; mean change in EDSS score at 2 years; mean change in
MSFC at 2 years; the number of patients who were unable to walk
without aid (EDSS > 5.5) at 2 years; mean change in PASAT at 2
years.
Available data was also not suitable for metanalysis of the mean
change in MFIS at 2 years. There are some trials included in
the trial register ClinicalTrials.gov (accessed 1 April, 2010) aimed
at evaluating NTZ for the relief of MS-related fatigue through
the MFIS (ENER-G study http://clinicaltrials.gov/ct2/show/
NCT00464074; TYNERGY study - http://clinicaltrials.gov/
ct2/show/NCT00884481 and http://clinicaltrials.gov/ct2/show/
NCT00966797); however these are open label trials with an ob-
servation period of less than 2 years. An open label trial indicated
significant improvement in MFIS scores after 6 months therapy
with NTZ compared to baseline (Putzki 2009). Moreover, pre-
liminary results indicate that MFIS scores decreased (improved)
significantly after the third NTZ infusion follow-up, compared to
baseline, in an open study of 186MS patients (Stephenson 2009).
We were unable to extract data from the paper by Balcer 2007,
which reported results from the AFFIRM 2006 and SENTINEL
2006 trials, in order to assess the number of patients experiencing
clinically significant worsening of vision at 2 years. This paper
demonstrated reduction in visual loss, as assessed by low-contrast
acuity testing, after NTZ treatment.
MRI parameters show statistical evidence in favour of participants
receiving NTZ versus controls.
Our analysis indicated that NTZ is well tolerated and safe over a
period of up to 2 years.
Serious AEs were less probable in the NTZ group than in the
control group. Since this could be due to the fact that the most
common serious AE in included trials was a MS relapse, which
was significantly more frequent in controls than in NTZ-treated
patients, MS relapses were excluded from the analysis and no dif-
ference in serious AEs was found.
We did not find evidence of potential liver injury with NTZ. This
problem raised interest in 2008 when a FDA safety review of NTZ
identified four cases of serious hepatic injury (http://www.fda.gov/
cder/dsn/2008˙spring/postmarketing.htm#natalizumab). None
of the cases resulted in death or liver transplant. As a consequence,
the “Warnings and Precautions” section of the product labelling was
updated to reflect this new safety information. Currently, moni-
toring liver enzymes is recommended before and during treatment
with NTZ.
In the NTZ arm of the AFFIRM study, one patient died of malig-
nant melanoma.He had a history of malignant melanoma and had
noted a new lesion at the time of receiving the first dose of NTZ.
In the literature, other cases of possible association between NTZ
and melanoma have been reported (Mullen 2008; Bergamaschi
2009; Ismail 2009; Laroni 2010). Whether this association is real
or coincidental remains to be seen.
About PML and other safety issues see “Overall completeness and
applicability of evidence”.
Not surprisingly, the PML cases have sensitized the neurologic
community to potential risks of NTZ, and this could result in
over-reporting of concomitant medical problems as potential AE
in NTZ-treated patients.
The number of patients experiencing at least one severe AE during
2 years did not differ between patients treated with NTZ and con-
trols. NTZ may cause HSRs and acute infusion reactions (Cohen
2010) but data emerging from this review is not alarming. Similar
to other protein-based therapies, NTZ may trigger these events
primarily in the first months of treatment. Most HSRs seem to
occur during the second infusion (Berger 2009; Phillips 2006,
AFFIRM 2006). HSRs and infusion-related AEs have been cor-
related with incidence of anti-NTZ antibodies (Calabresi 2007;
Cohen 2010). However, some cases of delayed allergic reactions
were reported or hypothesised in the absence of anti-NTZ an-
tibodies (Krumbholz 2007; Hellwig 2008; Cohen 2009; Zephir
2009; Killestein 2009).
It was difficult to calculate the number of patients who discontin-
ued the interventions because of AEs in the AFFIRM and SEN-
TINEL trials. Reasons for discontinuation from the study inter-
ventions were not available for the patients who “discontinued
study drug but completed follow-up” in the “participant flow” fig-
ures in the papers Polman 2006 (AFFIRM 2006 - Figure1, page
906) and Rudick 2006 (SENTINEL 2006 - Figure 1, page 915).
Therefore, the numbers used in the metanalysis were drawn from
percentages reported in the text. No statistically significant differ-
ence in rate of discontinuation because of AEs was found between
patients who took NTZ and those who did not. It is worth men-
tioning that patients who experienced any HSR (irrespective of
severity) were required by the protocol to discontinue the study
drug in the AFFIRM and SENTINEL trials (Biogen Idec and Elan
Pharmaceuticals 2006).
A well-established pharmacodynamic feature of NTZ is the in-
crease in number of circulating leukocytes. Counts return to base-
line levels when NTZ is discontinued. Thus, the increase in num-
ber of leukocytes was not reported among laboratory AEs.
No data was available regarding the number of patients experienc-
ing a relapse in the 4weeks after the first dose ofNTZ.We included
this outcome to assess the first-dose paradoxical reaction hypoth-
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esised in some reports (Centonze 2008; Haupts 2008; Haartsen
2009; Rinaldi 2009). It was speculated that NTZ can promote
the release of inflammatory mediators from lymphocytes present
in the CNS (Centonze 2008) or modify the regulatory network
in the brain (Rinaldi 2009) at the time of the first infusion, thus
favouring the clinical manifestation of a pre-existing active lesion.
A RCT (O’Connor 2004) aimed at evaluating the effects of a
single dose of IV NTZ 1 or 3 mg/kg (n=117) or placebo (n=63)
within 96 hours of the onset of a MS relapse, found that NTZ did
not effect the short-term clinical course of patients during acute
relapses; a significant decrease in Gd-enhancing lesion volume was
observed at 1 and 3 weeks after treatment. Moreover, there were
no differences in theNTZ versus placebo groups in the occurrence
of new acute relapses during a 14-week follow-up period.
Overall completeness and applicability of
evidence
The review’s aim was to assess NTZ’s efficacy, tolerability and
safety in patients with RRMS. In our view this review has reliably
assessed efficacy and short- and 2 year long-term tolerability and
safety.
As far as assessment of progression is concerned, included studies
required only 12 weeks of sustained EDSS worsening to classify
patient outcome as progression. As stated in the review protocol,
the preferred definition of progression included confirmation of
sustained EDSS increase at 6 months; one cannot exclude that
some patients classified as developing progressionmaymerely have
experienced a prolonged but still reversible disability after a relapse
and not an actual progression (Ebers 2008).
A limitation in the analysis of the PCS and MCS components of
SF-36 is the clinical significance of measured changes. A change of
5.0 points (SD, 0.5) is considered a clinically meaningful differ-
ence in a reference population of disease-free individuals (Norman
2003).
Tysabri® is available in many countries for treating RRMS. It has
marketing authorisation or recommendation as a single disease-
modifying therapy in patients with highly active RRMSor patients
who have had an inadequate response to, or are unable to toler-
ate, other current multiple sclerosis therapies (FDA 2006, EMA
2009, AIFA 2006, NICE 2007). The definition of highly active
RRMS differs slightly from country to country, but it can be said
to include: (i) failure to respond to a full and adequate course of
an interferon beta (IFNß - different types) or GA, with at least one
significant relapse in the previous year of therapy, and at least 9 T2-
hyperintense lesions on cranial MRI or at least one gadolinium-
enhancing lesion; (ii) previously untreated patients with rapidly
evolving severe RRMS defined by two or more disabling relapses
in 1 year, and 1 or more gadolinium-enhancing lesions on brain
MRI or a significant increase in T2 lesion load compared with
a previous MRI (EMA 2009, AIFA 2006, NICE 2007). In any
case, the variable licensed indications all over the world for the use
of NTZ represents a compromise between the need to provide a
more effective therapy for RRMS, the risk of PML and the cost
of implementation (Giovannoni 2007).
This review did not evaluate the question whether the clinical effi-
cacy of NTZ in the suboptimal therapy group can be considered to
be fully established. However, study populations included patients
with active MS, with clinical and MRI features similar to those
included in prescribing recommendations (even with some differ-
ences from country to country). As an example 38% of patients in
the combined SENTINEL 2006 and AFFIRM 2006 cohort had
twoormore relapses in the preceding year and 41%had at least one
gadolinium enhancing lesion on brain MRI. A post hoc analysis
of the AFFIRM study (Havrdova 2009, AFFIRM 2006) showed
that NTZ was superior to placebo (absence of disease activity on
combined clinical and radiological measures defined as no relapse,
no progression of disability sustained for 3 months, no Gd+ le-
sion, and no new or enlarging T2-hyperintense lesions) in both
highly active (≥ 2 relapses in the year before entry and≥ 1Gd+ le-
sion at entry) and non-highly active subgroups. Another post hoc
analysis of SENTINEL and AFFIRM studies (Hutchinson 2009)
found that NTZ reduced the annualised relapse rate and the risk
of sustained disability progression regardless of baseline disease or
demographic characteristics, except for the subgroup of patients
with less than 9 T2 lesions at baseline. The number of subjects in
the subgroup of patients with less than 9 T2 lesions at baseline is
so small (8% of the total population) that any speculation about
this result is futile in our opinion.
The primary outcomes of this review were set at 2 years of treat-
ment. No data from RCTs is available for longer treatment du-
ration. However, data from real-world cohorts of RRMS patients
who receivedmore than 36 infusions confirm the efficacy of NTZ
throughout the 3 years of treatment (O’Connor 2010, Horga
2010, Sangalli 2010). Another open question is the duration of
NTZ treatment and the effects of discontinuation. Two studies
report that patients who stopped NTZ experienced significant
clinical relapses and radiologic worsening within 6 months (West
2010; Killestein 2010). An immune reconstitution inflammatory
syndrome (IRIS) - like rebound of inflammatory MS activity after
discontinuation is also reported (Miravalle 2011).
What about early treatment? This question was not directly ad-
dressed but we can report that patients who participated in
AFFIRM 2006 had a median disease duration of 5 yrs (range 0-
34 yrs); 4% were diagnosed as having MS after a single clinical
attack according to McDonald criteria. As protocol violations, 13
patients (1.4%of the total population) in the AFFIRMstudywere
included even if only Clinically Isolated Syndrome (CIS) criteria
were satisfied (McDonald 2001). SENTINEL 2006 patients had
longer median disease duration (7 yrs; range 1-34 yrs). Thus, one
can conclude that NTZ was poorly studied as an early treatment
option in RRMS in these studies.
A limitation of this review’s external validity is the previous use
of DMDs, including immunosuppressants such as cyclophospha-
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mide, mitoxantrone, cyclosporine, azathioprine and methotrexate
(some of which are largely used off label in several countries). Only
55% of the combined SENTINEL 2006 and AFFIRM 2006 co-
hort (all patients in SENTINEL) had a duration ≥ 10 months
of IFNß therapy before the first dose of NTZ. Precise data on
immunosuppressant use prior to inclusion in the trials was not
available. Exclusion criteria included treatment with cyclophos-
phamide or mitoxantrone within the previous year or treatment
with cyclosporine, azathioprine or methotrexate within the previ-
ous 6months (Polman 2006, AFFIRM 2006) or with an approved
disease-modifying therapy other than IFNβ-1a intramuscularly
once weekly within the 12-month period before randomisation
(Rudick 2006, SENTINEL 2006). In practice a large number of
patients are treated with NTZ after the use of other DMDs, in-
cluding immunosuppressants and this fact may have an impact on
tolerability and safety issues.
Because of the demographic characteristics of the participants in
the trials included, the results of this review cannot be considered
valid for pediatric RRMS patients (for pediatric use see Ghezzi
2010) and for people with RRMS aged over 55 years or with
EDSS>5.
Pregnancy or conception planning were exclusion criteria in the
RCTs; hence teratogenicity and/or safety of NTZ in pregnancy
were not addressed. We can only quote published data on 98
pregnancies, from the TOUCH and TYGRIS studies, showing
that exposure to NTZ had no negative effect on pregnancy out-
comes (Bozic 2007). Since there is lack of data, NTZ is contraindi-
cated during pregnancy and there is a pregnancy exposure reg-
istry for Tysabri sponsored by Biogen Idec & Elan Pharmaceu-
ticals (http://clinicaltrials.gov/ct2/show/NCT00472992 accessed
9 April 2010).
This review did not intend to evaluate the impact of anti-NTZ
antibodies, which develop persistently in about 6% of treated pa-
tients; they are correlated with a higher incidence of AEs, as above
mentioned, as well as reduced efficacy (Calabresi 2007).
This review did not compare the efficacy of NTZ with other cur-
rently available DMDs in RRMS. Add-on studies are not as di-
rectly informative as monotherapy, however they provide evidence
of efficacy in a well defined setting. If we assume that IFNβ-1a
and NTZ do not interact in a synergistic manner, one might infer
from the results of the SENTINEL trial that NTZ appears more
efficacious than IFNß-1a once a week (i.e. Avonex) after 2 years
of treatment. What DMDs are available as alternatives to Tysabri
® in RRMS? In patients with suboptimal response to first line
options, it is acceptable to increase the dose if applicable or switch
to alternative first line treatments: e.g. high-dose IFNß if on low-
dose IFNß treatment (Panitch 2002; Sharief 2003; Schwid 2005);
GA in place of IFNß (Caon 2006; Zwibel 2006) or vice versa.
In Italy, and also in other countries, azathioprine and cyclophos-
phamide are used off-label in MS. Mitoxantrone is approved for
MS treatment world-wide (with some differences from country
to country), but it is cardiotoxic (Ghalie 2002) and the risk for
therapy-related leukaemia is increasingly reported (Straffi 2010).
Cross-trial comparisons are very controversial (Freedman 2008;
Goodin 2008a; Klawiter 2009). Earnshaw and collaborators, eval-
uating data for clinical trials and long-term clinical assessments
thereafter, found that GA or NTZ in RRMS patients is associated
with increased benefits compared with symptommanagement, al-
beit at higher costs, and that long-term lifetime cost effectiveness
is similar for NTZ and GA (Earnshaw 2009). The best way to
avoid any bias is to perform direct head-to-head comparisons of
therapies in the same population with adequate randomisation
and allocation concealment, clinically meaningful outcomes and
statistical power.
Another issue is how well current clinical and MRI criteria for
disease activity are measures of response to a particular therapy.
Future trials should deal with these issues. The trial entitled “A
Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-
Controlled Study to Evaluate the Effects of Switching Therapy
(Glatiramer Acetate or Interferon ß-1a) to NTZ in Subjects With
Relapsing Remitting Multiple Sclerosis (SURPASS)” intends to
study the outcome of switching to Tysabri® in subjects with ac-
tive RRMS despite receiving GA or IFNß-1a (Rebif®) for at least
12months (http://clinicaltrials.gov/ct2/show/NCT01058005 ac-
cessed 9 April 2010). Findings from such a study will provide
validation of proposed “activity” criteria, information about the
relative benefits of different treatment options with a significant
advancement toward optimising treatment in a high-risk MS pa-
tient population. IQUALYSEP is a randomised parallel single
blind cost-effectiveness trial comparing three years NTZ treat-
ment versus 6 months mitoxantrone treatment followed by im-
munomodulators for 2.5 years in RRMS defined as “aggressive”
(1 or more disabling relapses during the 12 months before inclu-
sion; EDSS between 2 and 5) (http://clinicaltrials.gov/ct2/show/
NCT01065727 accessed 9 April 2010).
A major limit of this review is the inability to provide an up-to-
date systematic assessment of long-term safety. Our protocol was
insufficient to evaluate rare and long-term AEs such as PML, can-
cers and other opportunistic infections, which are very important
issues in risk/benefit balancing.
PML is a demyelinating infectious CNS disease, usually observed
in immunodeficient patients, especially in AIDS patients, caused
by the human polyomavirus JC virus, a common and widespread
virus infecting humans (Koralnik 2004; Tan 2010). JC virus has
been identified in human post mortem brain samples from im-
munological normal individuals without PML (White 1992;Mori
1992). The pathogenesis of PML in patients receiving NTZ is
complex and not fully understood. PML causes death or severe
disability, either directly or as a result of IRIS. This syndrome is an
inflammatory response to JC virus associated with a rapid recov-
ery of the immune system after a period of immunosuppression.
Therefore, although a cellular immune response directed against
the JC virus is beneficial, a rapid global recovery of the immune
system might not always be favourable (Tan 2010). The issue of
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PML in MS therapies is not restricted to NTZ. Rituximab is a
potentially effective approach in the treatment of RRMS (Hauser
2008). PMLoccurred during rituximab treatment for hematologic
malignancies or autoimmune diseases (e.g. Rheumatoid Arthri-
tis, Systemic Lupus Erythematosus) (Biogen Idec Inc 2008). Aza-
thioprine has been associated with PML in some case reports in
different diseases (Schneider 1991, White 2002, Pagnoux 2003,
Gedizlioglu 2009). PML has also been described in a NTZ-treated
patient with Crohn’s disease (Van Assche 2005). NTZ has been
approved for CD in USA in January 2008. To our knowledge,
there have been no postmarketing reports of PML in patients
treated with Tysabri® for CD. Less than 2% of Tysabri® use in
the U.S. has been in patients with CD (US FDA 2009). The
FDA, EMEA, Biogen Idec & Elan Pharmaceuticals continue to
receive reports of PML inMS patients treated with Tysabri® . The
last update obtained from Biogen Idec and Elan Pharmaceuticals
dates December 2, 2010 (see http://www.biogenidec.ch accessed
31 December, 2010) when the number of patients with PML was
79 (34 in USA, 40 in Europe and 5 in the rest of the world) of
which 16 died (20%), out of 75500 patients exposed to Tysabri
® (exposure as of September 30, 2010). Surviving PML patients
have varying levels of disability, ranging from severe to mild. The
risk for developing PML in a patient treated with NTZ, initially
estimated to be 1:1000 at around 18 months (Yousry 2006), ap-
pears now to increase with the number of Tysabri infusions re-
ceived. On the basis of the total number of patients treated with
NTZ and the number of infusions, at 2 December 2010, Bio-
gen Idec & Elan Pharmaceuticals provided the following treat-
ment epoch risk of PML: ≤ 12 infusions = 0.01 per 1000 patients
(95% CI = 0 to 0.07 per 1000); 13-24 infusions = 0.38 per 1000
patients (95% CI = 0.23 to 0.60 per 1000); 25-36 infusions =
1.48 per 1000 patients (95% CI = 1.08 to 1.97 per 1000) and
the risk does not seem to increase further after 36 infusions (see
http://www.biogenidec.ch accessed 31 December, 2010). It must
be noted that around 31000 patients were exposed ≥24 months
and 12500 ≥36 months to Tysabri® (even this duration may not
fully reflect treatment interruptions that may have happened) (see
http://www.biogenidec.ch accessed 31 December, 2010). Accu-
mulating experience indicates that a history of prior immunosup-
pressant use is a risk factor for PML, which appears to be inde-
pendent of treatment duration. In terms of geographical distri-
bution, the possible higher risk of PML in Europe might be due
to greater use of immunosuppressant therapies for MS (Clifford
2010). In February 2010, the FDA provided a safety update that
noted an increased risk of getting PML with increasing number of
infusions, with the overall worldwide cumulative rate of PML in
patients who have received at least 24 infusions estimated as 1.3
cases of PML per 1000 patients. The agency concluded that the
benefits of the medicine continue to outweigh the risks (US FDA
2010). The European Medicines Agency (EMA) provided safety
updates along similar lines (EMA 2010). Currently, there are no
established interventions that can reliably prevent or adequately
treat PML, though some are reported (Wenning 2009; Clifford
2010; Warnke 2010). Large-scale, prospective clinical studies are
currently under way to determine whether a new JC virus assay will
help clinicians predict which patients are most at risk for PML (
STRATIFY-1 and STRATIFY-2). According to Thompson 2008,
more than a sevenfold increase in actual risk of PML was required
to decrease NTZ’s health gain below that of IFNß-1a (Rebif® 44
g).
Some controversial safety concerns have been raised in the last
few years about opportunistic infections other than PML as a re-
sult of prolonged suppression of immunosurveillance of the CNS
and other tissues: severe cutaneous Candida infection (Gutwinski
2010), ocular toxoplasmosis (Zecca 2009) and severe herpetic in-
fections (Ransohoff 2007). There was one fatal case of herpes sim-
plex encephalitis (that occurred 3 months after a single dose of
NTZ in a patient previously treated with the maximum lifetime
dose of mitoxantrone) and one case of herpes simplex meningitis
(that developed several hours after a single dose of NTZ) in the
post-marketingMS setting (Biogen Idec and Elan Pharmaceuticals
2006). It is currently too difficult to draw conclusions on the cau-
sation of these AEs. A single case of cryptosporidial gastroenteri-
tis occurred during the AFFIRM study (the event was considered
resolved 70 days after the symptoms first started - Biogen Idec
and Elan Pharmaceuticals 2006); this infection may also occur in
immunocompetent hosts and, in general, it is a self-limited illness
with an average time to recovery ranging from several days up to
5 weeks (Leav 2003).
Other infections (more or less classifiable as opportunistic or
atypical) have been reported in CD patients treated with NTZ,
including one case each of fatal Pneumocystis carinii pneumo-
nia, fatal Pulmonary aspergillosis, Mycobacterium avium com-
plex pneumonia, cytomegalovirus colitis, cytomegalovirus hepati-
tis, primary varicella pneumonia, Burkholderia cepacia pneumo-
nia, tubercle bacillus peritonitis, cavitating pneumonia with lung
abscess and Candida sepsis (Tysabri CD Briefing Book). It seems
that more patients with CD experienced opportunistic or atypical
infections than MS patients during NTZ treatment.
A possible association of NTZ treatment with lymphoma has been
postulated. Two cases of primary CNS lymphoma were reported
in MS patients: one was Epstein Barr virus negative (Schweikert
2009); for the other case, Epstein Barr virus staining results were
not available (Bozic 2009). A systemic B-cell lymphoma has been
reported in the ENCORE trial in a patient with CD after NTZ
treatment (Targan 2007).
Dysimmune disorders reported in relation to NTZ therapy have
been described, including autoimmune thrombocytopenia (Jones
2008) and autoimmune haemolytic anaemia (Outteryck 2009).
As a result of these concerns, mostly PML risk, NTZ is rec-
ommended in many countries as second-line therapy if conven-
tional immunomodulatory agents have failed or as first line ther-
apy in severe relapsing disease, as mentioned above (FDA 2004
and 2006, EMA 2009, AIFA 2006, NICE 2007). Immune com-
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petence is crucial before NTZ initiation. Expert recommenda-
tions (Gold 2007; Kappos 2007) includes: neutrophils > 1500
cells/ml, lymphocytes > 1000 cells/ml, CD4+ cells > 500 cells/ml
and CD8+ cells > 250 cells/ml; no history of opportunistic infec-
tions in the previous 3-6 months; immunosuppressive drugs (ex-
cept for standard steroid therapy for relapse) should be discontin-
ued at least 6 months before; immunomodulatory agents are con-
traindicated if concomitant and should be discontinued at least
6 weeks before. The contraindication of simultaneous treatment
with immunomodulatory agents and NTZ emerged from the fact
that the first 2 cases of PML in MS occurred in patients who
were part of the combination treatment arm of the SENTINEL
2006 trial. Beyond these guidelines and recommendations, an
important unknown faces the clinician: once a patient is started
on NTZ, it is currently unclear how duration of treatment with
NTZ impacts the risk-benefit ratio of this drug. The safety is-
sue of NTZ treatment is managed through active post-market-
ing surveillance programs that are currently being undertaken in
several countries. There is the Tysabri Global Observational Pro-
gram in Safety (TYGRIS) which is a voluntary 5000-patient reg-
istry cohort in North America (http://clinicaltrials.gov/ct2/show/
NCT00477113) and the rest of world (http://clinicaltrials.gov/
ct2/show/NCT00483847) with 5-year follow-up for infections
requiring hospitalisation, cases of PML, malignancies, and all AEs
that are serious or medically significant. The “Tysabri Outreach:
Unified Commitment to Health” (TOUCH®) is a mandatory
prescribing program started by Biogen Idec and Elan Pharma-
ceuticals in USA with the help of the Food and Drug Admin-
istration (FDA) and it is based on the restriction of NTZ pre-
scription to physicians participating in this risk management pro-
gram (http://www.tysabry.com; http://www.fda.gov/cder/drug/
infopage/natalizumab/RiskMAP.pdf). Reports from the TYGRIS
and TOUCH® studies show that the benefit-risk profile of NTZ
remains favourable for patientswithRRMS (Bozic 2009a). Tysabri
Observational Program (TOP) has been planned as an observa-
tional program in Europe, Australia and Canada with the pri-
mary aim of assessing long-term safety of 5,000 patients treated
with Tysabri in RRMS in the post-marketing setting (http://
clinicaltrials.gov/ct2/show/NCT00493298). NTZ is under in-
tensive monitoring by the Medicines and Healthcare products
Regulatory Agency (MHRA) accredited by the United Kingdom
National Health Service to provide drug safety updates (http:/
/www.mhra.gov.uk). Other examples are the Danish Multiple
Sclerosis Treatment Register (Oturai 2009), the Swedish Mul-
tiple Sclerosis registry (Piehl 2010), the Australian Prescribing
Program (TAPP), and the Italian Agenzia Italiana del Farmaco
(AIFA) pharmacovigilance electronic program (www.http://aifa-
neuro.agenziafarmaco.it; Mancardi 2010). Moreover, STRATA is
an ongoing open-label, multinational study evaluating the long-
term safety of Tysabri in participants who completed AFFIRM,
SENTINEL or GLANCE trials and a dosing suspension safety
evaluation, with no history of anti-NTZ antibodies (O’Connor
2010).
Thus, unlike mitoxantrone, for which the actual risks of serious
cardiotoxicity and leukaemia only became apparent as case series
were published, NTZ has a robust postmarketing safety monitor-
ing program involving a large number of NTZ-treated MS pa-
tients worldwide.
From the Cochrane Collaboration point of view, in light of these
uncertainties, an independent systematic updated review of the
safety profile of NTZ is warranted. Such a review for AEs should
be based on different eligibility criteria for selecting studies. The
use of different eligibility criteria specifically addresses the problem
that RCTs are insufficient to evaluate rare and long-term AEs. AEs
may be studied across different indications such as CD, Rheuma-
toid Arthritis and rare neurological diseases (eg multifocal motor
neuropathy - Raji 2009; Susac syndrome - Lee 2009).
Quality of the evidence
The two larger included studies were classified as having good
methodological quality. This is in line with the fact that they also
satisfy definition of Class I studies according to the system used by
the AmericanAcademy ofNeurology for therapeutic interventions
(Goodin 2008). The quality of evidence for each of the primary
outcomemeasures of the reviewwas good, even if bias could not be
definitively excluded (see “Potential biases in the review process”).
The two MRI-based secondary outcomes and the other available
secondary outcomes confirmed superiority of NTZ treatment, al-
lowing a robust conclusion regarding the main objectives of the
review.
Showing both absolute and relative measures for each outcome is
a more transparent evaluation of data, considering the different
weight that several variables (e.g. frequency of the events studied,
baseline patient characteristics, and so on) have on such measures.
We accomplished such a need by reporting both RR and NNB
values.
Potential biases in the review process
All relevant studies were identified. The International Natal-
izumab Multiple Sclerosis Trial Group (INMSTG 2003) was a
“study awaiting classification” but we hope to obtain data, from
authors or sponsors, for inclusion in pooled data of safety/tolera-
bility outcomes in an updated future version of this review. Seem-
ingly, the exclusion of this data does not effect results on safety/
tolerability.
Single dose trials and trials using dose≤ 3mg/kgwere not included
in the present review (Table 6), since these are dosages significantly
lower than the dosage approved in clinical practice.
Our review is not able to provide data about the possible biasing
effect of protocol violations on the results. During the US FDA
evaluation process of NTZ in RRMS, the CDER judged the vio-
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lations as minor, stating that they “would not be expected to affect
the results directionally” (FDA 2004 - page 38).
We found heterogeneity for the 2 primary outcomes “number of
patients who experienced a relapse at 2 yrs” and “number of pa-
tients who experienced progression at 2 yrs”, but sensitivity analy-
sis did not change conclusions. The heterogeneity may be clearly
ascribed to the fact that the SENTINEL 2006 trial was an add-
on study, with an active treatment control group. Also, AFFIRM
2006 and SENTINEL 2006 populations differed from each other.
SENTINEL 2006 had to meet the inclusion criterion of break-
through disease while on IFNß-1a IMmonotherapy. On the other
hand, patients who had received treatment with IFNß or GA for
more than six months were excluded in AFFIRM 2006.
The type of ITT analysis was not described in the papers reporting
included trials. ITT statements with no further details carry an
unclear risk of bias.
All the data of the present review was from trials supported by Bio-
gen Idec and Elan Pharmaceuticals. In agreement with Cochrane
Collaboration policy, this may be considered as a potential risk of
bias. We included Table 6 for the sake of completeness in reporting
features of excluded trials which were sponsored.
Agreements and disagreements with other
studies or reviews
Our review is in agreement with other papers which reviewed
NTZ (Hutchinson 2007; Yaldizli 2009; Coyle 2009) and with the
Report of the Therapeutics and Technology Assessment Subcom-
mittee of the American Academy of Neurology (Goodin 2008).
Of notable mention is the post-hoc reassessment of data from the
AFFIRM trial made by Havrdova 2009 (AFFIRM 2006) which
used as outcome the proportion of patients with absence of disease
activity (defined as no relapses, no sustained disability progression,
no gadolinium-enhancing lesions, no new or enlarging T2-hyper-
intense lesions on cranial MRI). This type of outcome could be
an increasingly attainable goal in RRMS treatment and could be
of interest for future Cochrane reviews.
Several real-life experiences confirm the efficacy and tolerability of
NTZ in RRMS (Mancardi 2010, Piehl 2010, Putzki 2010, Putzki
2010a, Belachew 2010, Outteryck 2010, Ghezzi 2010).
Additional comments
Arriving at the best treatment option for an individual MS patient
needs an open and realistic discussion of MS natural history, the
therapeutic benefits and risks of each available DMT (paying at-
tention to the insurmountable cross-trial comparison issues), and
the patient’s own disease history. It is ultimately the patient’s de-
cision to refuse or accept the relevant risks related to a treatment.
People tend to underestimate common risk and overestimate rare
risk. They respond to risks primarily on the basis of emotion rather
than facts. They seem to be risk averse when faced with medical
interventions, and want information on even the rarest of adverse
events (Moore 2008). Denial and other defence mechanisms may
make them less capable of weighing pros and cons to a treatment
like NTZ. Treatment decisions are based on facts and emotions,
both of which may be manipulated. Many factors contribute to
an incomplete understanding of the available evidence on risk by
both patients and health professionals (Moore 2008). Moreover,
studies have revealed communication and information deficits in
the context of MS care (Freeman 2000, Vickrey 2000, Heesen
2004, Solari 2007) and heterogeneity in patients’ preference in
their involvement in decisions regarding their care. As an exam-
ple, data on Italian MS patients indicates a preference for infor-
mation but less involvement in decision-making (i.e. more passive
role) in more than 30% of cases (Giordano 2008). These prefer-
ences vary from country to country, for example comparing Italian
with German MS patients (Giordano 2008). A passive attitude
may create a marked difficulty during the decision-making pro-
cess about a treatment like NTZ. On the contrary, a more active
role may be associated with the fact that patients were willing to
accept a higher risk of PML than neurologists, and more willing
to continue treatment with NTZ as reported by Heesen 2010.
Open information about treatment-related risks was appreciated
by German MS patients and considered important in supporting
shared decision making (Heesen 2010). Although evidence-based
medicine strives to reduce medical decision-making to standard-
ized, codified recommendations, it is the judgment of the neu-
rologist and the personal choice of the patient that ultimately de-
termine the treatment plan. Whereas all therapeutic decisions are
ultimately in the hands of the patients, their decisions are heavily
influenced by the manner in which clinicians present the choices
to them. Although the first precept may be “do no harm,” if this
was taken too far to mean that the risks of all complications should
be eliminated, we would be discouraging interventions that on
average produce benefits.
More studies about patients’ preferences, physicians’ communica-
tion skills, methodology to enhance communication and patients’
evaluation of treatment efficacy and risks are needed. This is not
restricted to NTZ, since it is clear that all future therapies that
effectively act on the immune system will similarly require analysis
of risks and prolonged postmarketing surveillance to determine
their safety profiles. As the treatment paradigm of MS evolves and
newer agents become available, making treatment decisions and
providing skilled guidance for patients will becomemore challeng-
ing for neurologists and health service providers.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In patients with RRMS, we found a consistent positive effect of
NTZ in reducing relapses and disability at 2 years. NTZ was well
tolerated but information on the frequency and nature of AEs was
limited to a short follow-up period. There are significant safety
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concerns about PML which is increasingly reported in the post-
marketing setting. NTZ should be used only by skilled neurol-
ogists in MS centres under national or international surveillance
programs.
Implications for research
Because of safety concerns and the substantial expense related to
NTZ, future research should be aimed at:
• further study of the use of NTZ in suboptimal therapy
RRMS patients;
• comparing benefit/risk and cost-effectiveness profiles
between NTZ and current agents in naive RRMS patients
through head-to-head trials;
• comparing benefit/risk and cost-effectiveness profiles
through head to head trials between NTZ and new emerging
agents in RRMS;
• development and validation of clinical and MRI criteria for
reliably assessing disease activity in treatment trials;
• cohort studies investigating predictive parameters of long-
term NTZ effectiveness in clinical practice;
• exploring the possible detrimental first-dose effect on
relapse, including its prevention;
• investigating and optimising the use of NTZ as induction
therapy, with the minimum number of infusions to reduce the
risk of PML;
• further study of the risk of PML, other opportunistic
infections and cancer during NTZ treatment, evaluating risk
threshold on the basis of the number of infusions;
• identifying risk factors for PML at baseline and during
treatment;
• optimising best practice to monitor patients during NTZ
therapy to facilitate early diagnosis of PML;
• further study on the optimum duration of NTZ treatment;
• assessing the best options for treating PML and IRIS in MS
patients exposed to NTZ;
• evaluating the cost-effectiveness of increasing the current 4
week time interval between infusions;
• enhancing strategies for decision making and patient
empowerment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AFFIRM 2006
Methods Phase 3, multicentre, randomised, double-blind, placebo controlled trial
Participants 99 centers in Europe, North America, Australia, and New Zealand enrolled 942 patients
recruited from November 6, 2001 to January 31, 2005. Inclusion criteria: age=18-50
years, diagnosis of RRMS (McDonald criteria), EDSS=0-5.0; at least one medically
documented relapse within the 12 months before the study began
Exclusion criteria: a relapsewithin 50days before the administration of the first dose of the
study drug; treatment with cyclophosphamide or mitoxantrone within the previous year,
or treatment with IFNß, GA, cyclosporine, azathioprine, methotrexate, or intravenous
immune globulin within the previous 6 months; treatment with IFNß, GA, or both for
more than six months
Interventions Patients were randomly assigned in a 2:1 ratio to receive either NTZ (at a dose of 300
mg) or placebo by intravenous infusion every 4 weeks for up to 116 weeks
Outcomes Primary endpoints: rate of clinical relapse at 1 year; rate of sustained progression of
disability at 2 years, as measured by EDSS, defined as an increase of 1.0 or more on
the EDSS from a baseline score of 1.0 or more or an increase of 1.5 or more from a
baseline score of 0, that was sustained for 12 weeks (progression could not be confirmed
during a relapse). Secondary endpoints: different MRI parameters at 1 and 2 years; the
proportion of relapse free patients at 1 year; rate of clinical relapse at 2 years; progression
of disability at 2 years, as measured byMSFC. Tertiary endpoints: Visual function testing
(Sloan charts) ; Physical Component Summary (PCS) andMental Component Summary
(MCS) from SF-36; Subject Global Assessment Visual Analog Scale
Notes 3 patients who were assigned to receive placebo were never treated; these patients were
included in the intention-to-treat efficacy analyses but were excluded from the safety
analyses
Binding antibodies against NTZ were assessed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk quote “Patients were randomly assigned in
a 2:1 ratio to treatment that was stratified
according to study site in blocks of three
(two active, one placebo) with the use of
a computer-generated block randomisation
schedule”
Allocation concealment (selection bias) Low risk quote: “a multi digit identification num-
ber, implemented by an interactive voice-
response system was used ”
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AFFIRM 2006 (Continued)
Blinding (performance bias and detection
bias)
objective outcomes
Low risk quote: “All study personnel, patients, spon-
sor personnel involved in the conduct of the
study, and the investigator advisory com-
mittee were unaware of treatment assign-
ments throughout the study”
Blinding (performance bias and detection
bias)
subjective outcomes
Low risk quote: “All study personnel, patients, spon-
sor personnel involved in the conduct of the
study, and the investigator advisory com-
mittee were unaware of treatment assign-
ments throughout the study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk quote: “8 percent of patients in the
NTZ group and 10 percent of those in
the placebo group) withdrew from the
study. Thirty-nine patients discontinued
the study drug but completed follow-up (a
total of 4 percent, including 4 percent of
patients in theNTZ group and 5 percent of
those in the placebo group)”. “All analyses
followed the intention-to-treat principle.”
A CONSORT flowchart is shown.
However, the AFFIRM Authors did not re-
port how the outcomes for patient with-
drawals were assigned in the ITT analysis
Selective reporting (reporting bias) Low risk No selective reporting was identified.
Independent Funding Source High risk Supported by Biogen Idec and Elan Phar-
maceuticals. Data were
analysed by Biogen Idec and Elan Pharma-
ceuticals.
GLANCE 2009
Methods Phase 2, multicentre, randomised, double-blind, add-on, placebo-controlled, parallel-
group study
Participants 110 patients from 25 centres in US and Canada (between June 17, 2003 and March 23,
2004. Eligible patients: aged 18-55 years, diagnosis of RRMS (McDonald criteria), EDSS
= 0-5.0, treatment with GA for at least 12 months before randomisation, one or more
relapses during that time. Exclusion criteria: diagnosis of progressive MS, MS relapse
within 50 days before randomisation, clinically significant infectious illness within 30
days of randomisation, abnormal laboratory results (or history thereof ) indicative of any
major organ system disease precluding administration of NTZ or GA, history of severe
allergic or anaphylactic reactions, known drug hypersensitivity, or history of malignancy
(excluding nonmetastatic basal cell carcinoma). Women who were pregnant, at risk of
or planning to become pregnant, or breast-feeding were excluded
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GLANCE 2009 (Continued)
Interventions IV NTZ 300 mg or placebo once every 4 weeks plus GA 20 mg subcutaneously once
daily for 24 weeks
Outcomes Primary endpoint: rate of development of new active lesions on cranial MRI. Secondary
endpoints: AEs
Notes Aims: safety and tolerability data. The main hypothesis was that, because the proposed
mechanism of action of GA requires cellular entry into the brain, NTZ might impair
rather than enhance the efficacy of GA
Binding antibodies against NTZ were assessed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk quote:“Patients were randomly assigned 1:
1 to receive IV NTZ 300 mg or placebo”
However, the investigators did not describe
a random component in the sequence gen-
eration process
Allocation concealment (selection bias) Unclear risk unclear
Blinding (performance bias and detection
bias)
objective outcomes
Low risk quote:“All study personnel, patients, and
sponsor personnel involved in study con-
duct were blinded to treatment assign-
ments”
Blinding (performance bias and detection
bias)
subjective outcomes
Low risk quote: “All study personnel, patients, and
sponsor personnel involved in study con-
duct were blinded to treatment assign-
ments”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A CONSORT flowchart is shown.
However, the GLANCE Authors did not
report how the outcomes for patient with-
drawals were assigned in the ITT analysis
Selective reporting (reporting bias) Low risk No selective reporting was identified.
Independent Funding Source High risk This study was supported by Biogen Idec,
Inc. and Elan Pharmaceuticals, Inc
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SENTINEL 2006
Methods Phase 3, multicentre, randomised, double-blind, add-on, placebo controlled trial
Participants 124 centers in Europe and US enrolled 1196 patients beginning on January 14, 2002
up to February 28, 2005 (planned May 31, 2005). Inclusion criteria: age=18-55 years;
diagnosis of RRMS (McDonald criteria), EDSS=0-5.0; at least one relapse within the
12 months before randomisation; treatment with IFNß-1a im for at least 12 months
before randomisation. Exclusion criteria: a relapse within 50 days before randomisation;
treatment with an approved disease-modifying therapy other than IFNß-1a im once
weekly within the 12-month period before randomisation
Interventions Patients were randomly assigned, in a 1:1 ratio, to receive 300 mg of NTZ (589 patients)
or placebo (582 patients) intravenously every 4 weeks in addition to IFNß-1a (Avonex,
Biogen Idec) at a dose of 30 µg intramuscularly once weekly for up to 116 weeks
Outcomes Primary endpoints: rate of clinical relapse at 1 year; rate of sustained progression of
disability at 2 years, as measured by EDSS, defined as an increase of 1.0 or more on the
EDSS from a baseline score of 1.0 or more or an increase of 1.5 or more from a baseline
score of 0, that was sustained for 12 weeks (progression could not be confirmed during
a relapse)
Secondary endpoints: different MRI parameters at 1 and 2 years; the proportion of
relapse free patients at 1 year; rate of clinical relapse at 2 years; progression of disability
at 2 years, as measured by MSFC
Tertiary endpoints: Visual function testing (Sloan charts) ; Physical Component Sum-
mary (PCS) and Mental Component Summary (MCS) from SF-36
Notes One center with 25 patients was excluded before unblinding owing to irregularities in
data. Thus, the number of patients included in data analysis was 1171
Following the recognition of two cases of PML in patients who had been receiving
NTZ in combination with IFNß-1a (Avonex®) for over 2 years, Biogen Idec and Elan
Pharmaceuticals, in discussions with FDA, suspended commercialisation and clinical
trials on 28 February 2005
Binding antibodies against NTZ were assessed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk quote: “Randomization was stratified ac-
cording to study site in blocks of four (two
active and two placebo) with the use of a
computer-generated schedule”
Allocation concealment (selection bias) Low risk quote: “a multidigit identification num-
ber, implemented by an interactive voice-
response system was used ”
Blinding (performance bias and detection
bias)
objective outcomes
Low risk quote: “All study personnel, patients, spon-
sor personnel involved in the conduct of the
study, and members of the investigator ad-
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SENTINEL 2006 (Continued)
visory committee were blinded to the treat-
ment assignments throughout the study”
Blinding (performance bias and detection
bias)
subjective outcomes
Low risk quote: “All study personnel, patients, spon-
sor personnel involved in the conduct of the
study, and members of the investigator ad-
visory committee were blinded to the treat-
ment assignments throughout the study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk quote: “12 percent of the group assigned
to IFNß-1a plus NTZ and 16 percent of
the group assigned to IFNß-1a alone) with-
drew from the study”. “5 percent of the
combination-therapy group and 6 percent
of the group assigned to IFNß-1a alone dis-
continued the study drug but completed
follow-up ”. “ All analyses followed the in-
tention-to-treat principle.”
A CONSORT flowchart is shown.
However, the SENTINEL authors did not
report how the outcomes for patient with-
drawals were assigned in the ITT analysis
Selective reporting (reporting bias) Low risk No selective reporting was identified.
Independent Funding Source High risk Supported by Biogen Idec and Elan Phar-
maceuticals.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
UK Antegren Study 1999 Dosage: 3 mg/kg.
Characteristics of studies awaiting assessment [ordered by study ID]
INMSTG 2003
Methods Randomized, double-blind trial, placebo-controlled.
Participants 213 patients with RRMS or relapsing SPMS.
Interventions Three arms: (i) 3 mg of intravenous NTZ per kilogram of body weight (N=68), (ii) 6 mg per kilogram (N=74), (iii)
placebo (N=71) every 28 days for 6 months
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INMSTG 2003 (Continued)
Outcomes The primary end point was the number of new brain lesions on monthly gadolinium-enhanced MRI during the six-
month treatment period. Other MRI outcomes included the number of persistent enhancing lesions; the volume of
enhancing lesions; the number of new active lesions (the number of new enhancing lesions plus the number of new
or newly enlarging, nonenhancing lesions on T2-weighted MRI); and the number of scans showing one or more new
enhancing lesions. Secondary and tertiary clinical end points included
the frequency of relapse, EDSS changes, and patients’ own assessments of well-being
Notes Since the trial duration was 6 months, this study was included with the sole aim of assessing tolerability/safety data.
Data on RRMS only in the 6 mg per
kilogram arm are pending.
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D A T A A N D A N A L Y S E S
Comparison 1. Primary Efficacy Outcome (Natalizumab vs Control)




participants Statistical method Effect size
1 N of pts with at least one relapse
at 2 yrs
2 2113 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.47, 0.69]
1.1 Natalizumab vs Placebo 1 942 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.44, 0.61]
1.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.55, 0.70]
2 N of pts who progressed at 2 yrs 2 2113 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.62, 0.89]
2.1 Natalizumab vs Placebo 1 942 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.55, 0.81]
2.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.69, 0.93]
3 PCS Change in Short Form
(SF-36) follow up 2 years
2 2113 Mean Difference (IV, Random, 95% CI) 1.98 [1.05, 2.91]
3.1 Natalizumab vs Placebo 1 942 Mean Difference (IV, Random, 95% CI) 2.01 [0.48, 3.54]
3.2 Natalizumab + IFN vs
IFN
1 1171 Mean Difference (IV, Random, 95% CI) 1.96 [0.79, 3.13]
4 MCS Change in Short Form
(SF-36) follow up 2 years
2 2113 Mean Difference (IV, Random, 95% CI) 1.38 [0.33, 2.42]
4.1 Natalizumab vs Placebo 1 942 Mean Difference (IV, Random, 95% CI) 2.53 [0.00, 5.06]
4.2 Natalizumab + IFN vs
IFN
1 1171 Mean Difference (IV, Random, 95% CI) 1.14 [-0.00, 2.28]
Comparison 2. Secondary Efficacy Outcome (Natalizumab vs Control)




participants Statistical method Effect size
1 Change in Well-being (VAS) at
2 yrs
1 942 Mean Difference (IV, Random, 95% CI) 6.4 [1.76, 11.04]
1.1 Natalizumab vs Placebo 1 942 Mean Difference (IV, Random, 95% CI) 6.4 [1.76, 11.04]
2 Gd-enhacing lesion (at least one)
at 2 yrs
2 2113 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.09, 0.17]
2.1 Natalizumab vs Placebo 1 942 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.07, 0.17]
2.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.09, 0.22]
3 Change of MRI T2 total lesion
load at 2 yrs
1 855 Mean Difference (IV, Random, 95% CI) -3796.20 [-5849.43,
-1742.97]
3.1 Natalizumab vs Placebo 1 855 Mean Difference (IV, Random, 95% CI) -3796.20 [-5849.43,
-1742.97]
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Comparison 3. Primary Safety Outcome (Natalizumab vs Control)




participants Statistical method Effect size
1 N of pts with Severe AE over 2
yrs
2 2110 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.81, 1.04]
1.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.68, 1.08]
1.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.81, 1.10]
2 N of pts with Serious AE
(irrespective of treatment
duration)
3 2220 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.70, 0.98]
2.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.61, 1.02]
2.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.69, 1.09]
2.3 Natalizumab + GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.05, 5.36]
3 N of pts with serious AE
(irrespective of treatment
duration - MS relapses
excluded)
3 2220 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.90, 1.43]
3.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.81, 1.73]
3.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.81, 1.49]
3.3 Natalizumab + GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.06, 15.59]
Comparison 4. Secondary Safety Outcome (Natalizumab vs Control)




participants Statistical method Effect size
1 N of pts with at least one AE
(irrespective of treatment
duration)
3 2220 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.99, 1.01]
1.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.96, 1.02]
1.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.99, 1.01]
1.3 Natalizumab + GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.10]
2 Treatment Discontinuation
caused by AE (irrespective of
treatment duration)
3 2220 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.82, 1.59]
2.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.84, 2.97]
2.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.68, 1.50]
2.3 Natalizumab + GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.06, 15.59]
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Comparison 5. Adverse Event Analysis




participants Statistical method Effect size
1 Headache 3 2220 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.97, 1.20]
1.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.95, 1.39]
1.2 Natalizumab IFN vs IFN 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.92, 1.19]
1.3 Natalizumab + GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.63, 2.03]
2 Pain in arms or legs - Arthralgia 3 2220 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.98, 1.40]
2.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.98, 1.85]
2.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.85, 1.31]
2.3 Natalizumab + GA vs GA 1 110 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.60, 41.42]
3 Depression 3 2220 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.98, 1.41]
3.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.88, 1.60]
3.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.92, 1.47]
3.3 Natalizumab + GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.26, 8.63]
4 Anxiety 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.49 [1.05, 2.12]
4.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.49 [1.05, 2.12]
5 Insomnia 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.82, 1.36]
5.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.82, 1.36]
6 Influenza Like Illness 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.83, 1.33]
6.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.83, 1.33]
7 Nasopharyngitis 2 1281 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.94, 1.26]
7.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.96, 1.29]
7.2 Natalizumab + GA vs GA 1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.27, 1.52]
8 Pharyngitis 2 2110 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.98, 2.04]
8.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.81, 1.79]
8.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.76 [1.07, 2.90]
9 Sinusitis 2 1281 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.88, 1.88]
9.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.93, 1.56]
9.2 Natalizumab + GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 2.25 [0.74, 6.87]
10 Sinus Congestion 1 1171 Risk Ratio (M-H, Random, 95% CI) 2.03 [1.15, 3.59]
10.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 2.03 [1.15, 3.59]
11 Sinus Headache 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.69 [0.94, 3.03]
11.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.69 [0.94, 3.03]
12 Upper Respiratory Infection 3 2220 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.87, 1.28]
12.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.80, 1.26]
12.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.76, 1.69]
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12.3 Natalizumab + GA vs
GA
1 110 Risk Ratio (M-H, Random, 95% CI) 1.8 [0.64, 5.03]
13 Influenza 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.87, 1.48]
13.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.87, 1.48]
14 Cough 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.87, 1.75]
14.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.87, 1.75]
15 Diarrhea 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.93, 1.53]
15.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.93, 1.53]
16 Nausea 2 1281 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.88, 1.46]
16.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.87, 1.48]
16.2 Natalizumab + GA vs
GA
1 110 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.47, 2.70]
17 Vomiting 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.88, 2.22]
17.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.88, 2.22]
18 Abdominal Pain or Discomfort 2 2110 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.84, 1.55]
18.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.74, 1.65]
18.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.74, 1.92]
19 Muscle Cramp 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.74, 1.92]
19.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.74, 1.92]
20 Myalgia 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.95, 1.81]
20.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.95, 1.81]
21 Seasonal Allergy 1 1171 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.90, 2.51]
21.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.90, 2.51]
22 Peripheral Edema 1 1171 Risk Ratio (M-H, Random, 95% CI) 4.78 [2.00, 11.42]
22.1 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 4.78 [2.00, 11.42]
23 Tremor 2 2110 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.89, 2.27]
23.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.48, 2.29]
23.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.69 [0.94, 3.03]
24 Flushing 1 110 Risk Ratio (M-H, Random, 95% CI) 6.00 [0.75, 48.21]
24.1 Natalizumab GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 6.00 [0.75, 48.21]
25 Fatigue - Myasthenia 1 939 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.99, 1.64]
25.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.99, 1.64]
26 Urinary Urgency / Frequency 1 939 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.79, 2.03]
26.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.79, 2.03]
27 Hypersensitivity reactions 3 2220 Risk Ratio (M-H, Random, 95% CI) 3.43 [0.33, 36.07]
27.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 25.42 [1.55, 416.15]
27.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 5.43 [1.21, 24.41]
27.3 Natalizumab GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 4.07]
28 Chest Discomfort 1 939 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.83, 3.56]
28.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.83, 3.56]
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29 Local Bleeding 1 939 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.64, 3.91]
29.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.64, 3.91]
30 Rigors 2 1049 Risk Ratio (M-H, Random, 95% CI) 3.54 [1.16, 10.83]
30.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 3.15 [0.94, 10.57]
30.2 Natalizumab GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 7.0 [0.37, 132.40]
31 Syncope 1 939 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.48, 2.29]
31.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.48, 2.29]
32 Urinary Infection 2 1049 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.51, 1.93]
32.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.88, 1.57]
32.2 Natalizumab GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.13, 1.90]
33 Lower Respiratory Infection 1 939 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.78, 1.45]
33.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.78, 1.45]
34 Tonsillitis 1 939 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.78, 2.39]
34.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.78, 2.39]
35 Gastroenteritis 1 939 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.81, 1.86]
35.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.81, 1.86]
36 Vaginitis 1 939 Risk Ratio (M-H, Random, 95% CI) 1.65 [1.01, 2.71]
36.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.65 [1.01, 2.71]
37 Menstrual disorders 1 939 Risk Ratio (M-H, Random, 95% CI) 1.89 [1.09, 3.29]
37.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.89 [1.09, 3.29]
38 Skin Rash 2 1049 Risk Ratio (M-H, Random, 95% CI) 1.94 [0.47, 7.99]
38.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.81, 1.86]
38.2 Natalizumab + GA vs
GA
1 110 Risk Ratio (M-H, Random, 95% CI) 6.00 [0.75, 48.21]
39 Dermatitis 2 1049 Risk Ratio (M-H, Random, 95% CI) 2.15 [0.96, 4.85]
39.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.82 [0.98, 3.40]
39.2 Natalizumab + GA vs
GA
1 110 Risk Ratio (M-H, Random, 95% CI) 6.00 [0.75, 48.21]
40 Pruritus 1 939 Risk Ratio (M-H, Random, 95% CI) 2.07 [0.86, 5.00]
40.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 2.07 [0.86, 5.00]
41 Vertigo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.67, 2.09]
41.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.67, 2.09]
42 Infection 3 2220 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.97, 1.06]
42.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.93, 1.07]
42.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.97, 1.08]
42.3 Natalizumab + GA vs
GA
1 110 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.69, 1.22]
43 Infusion reactions 3 2220 Risk Ratio (M-H, Random, 95% CI) 1.24 [1.05, 1.47]
43.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.34 [1.01, 1.77]
43.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.97, 1.49]
43.3 Natalizumab + GA vs
GA
1 110 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.31, 2.39]
44 Back Pain 1 110 Risk Ratio (M-H, Random, 95% CI) 2.25 [0.74, 6.87]
44.1 Natalizumab +GA vs GA 1 110 Risk Ratio (M-H, Random, 95% CI) 2.25 [0.74, 6.87]
45 Fall 2 2110 Risk Ratio (M-H, Random, 95% CI) 2.69 [0.32, 22.39]
46 Neoplasms 3 2220 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.19, 3.66]
46.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 2.49 [0.29, 21.20]
46.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.19, 1.31]
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46.3 Natalizumab + GA vs
GA
1 110 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47 Abnormal liver function tests 1 939 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.67, 2.47]
47.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.67, 2.47]
48 Death 3 2220 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.14, 6.04]
48.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 2.49 [0.12, 51.75]
48.2 Natalizumab + GA vs
GA
1 110 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
48.3 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.04, 5.43]
49 MS relapse as a serious AE 3 2220 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.37, 0.68]
49.1 Natalizumab vs Placebo 1 939 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.30, 0.70]
49.2 Natalizumab + IFN vs
IFN
1 1171 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.36, 0.86]
49.3 Natalizumab + GA vs
GA
1 110 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.01]
Analysis 1.1. Comparison 1 Primary Efficacy Outcome (Natalizumab vs Control), Outcome 1 N of pts with
at least one relapse at 2 yrs.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 1 Primary Efficacy Outcome (Natalizumab vs Control)
Outcome: 1 N of pts with at least one relapse at 2 yrs








1 Natalizumab vs Placebo
AFFIRM 2006 173/627 169/315 45.5 % 0.51 [ 0.44, 0.61 ]
Subtotal (95% CI) 627 315 45.5 % 0.51 [ 0.44, 0.61 ]
Total events: 173 (Experimental), 169 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.99 (P < 0.00001)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 230/589 365/582 54.5 % 0.62 [ 0.55, 0.70 ]
Subtotal (95% CI) 589 582 54.5 % 0.62 [ 0.55, 0.70 ]
Total events: 230 (Experimental), 365 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.82 (P < 0.00001)
Total (95% CI) 1216 897 100.0 % 0.57 [ 0.47, 0.69 ]
Total events: 403 (Experimental), 534 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.45, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 5.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.45, df = 1 (P = 0.06), I2 =71%
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Analysis 1.2. Comparison 1 Primary Efficacy Outcome (Natalizumab vs Control), Outcome 2 N of pts who
progressed at 2 yrs.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 1 Primary Efficacy Outcome (Natalizumab vs Control)
Outcome: 2 N of pts who progressed at 2 yrs








1 Natalizumab vs Placebo
AFFIRM 2006 154/627 116/315 43.5 % 0.67 [ 0.55, 0.81 ]
Subtotal (95% CI) 627 315 43.5 % 0.67 [ 0.55, 0.81 ]
Total events: 154 (Experimental), 116 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.98 (P = 0.000068)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 194/589 239/582 56.5 % 0.80 [ 0.69, 0.93 ]
Subtotal (95% CI) 589 582 56.5 % 0.80 [ 0.69, 0.93 ]
Total events: 194 (Experimental), 239 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0042)
Total (95% CI) 1216 897 100.0 % 0.74 [ 0.62, 0.89 ]
Total events: 348 (Experimental), 355 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.09, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 3.29 (P = 0.0010)
Test for subgroup differences: Chi2 = 2.09, df = 1 (P = 0.15), I2 =52%
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Analysis 1.3. Comparison 1 Primary Efficacy Outcome (Natalizumab vs Control), Outcome 3 PCS Change
in Short Form (SF-36) follow up 2 years.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 1 Primary Efficacy Outcome (Natalizumab vs Control)
Outcome: 3 PCS Change in Short Form (SF-36) follow up 2 years





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Natalizumab vs Placebo
AFFIRM 2006 627 0.67 (11.28) 315 -1.34 (11.26) 37.0 % 2.01 [ 0.48, 3.54 ]
Subtotal (95% CI) 627 315 37.0 % 2.01 [ 0.48, 3.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.0098)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 589 1.03 (10.2) 582 -0.93 (10.2) 63.0 % 1.96 [ 0.79, 3.13 ]
Subtotal (95% CI) 589 582 63.0 % 1.96 [ 0.79, 3.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.29 (P = 0.0010)
Total (95% CI) 1216 897 100.0 % 1.98 [ 1.05, 2.91 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 4.18 (P = 0.000029)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 1.4. Comparison 1 Primary Efficacy Outcome (Natalizumab vs Control), Outcome 4 MCS Change
in Short Form (SF-36) follow up 2 years.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 1 Primary Efficacy Outcome (Natalizumab vs Control)
Outcome: 4 MCS Change in Short Form (SF-36) follow up 2 years





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Natalizumab vs Placebo
AFFIRM 2006 627 2 (18.67) 315 -0.53 (18.67) 17.0 % 2.53 [ 0.00, 5.06 ]
Subtotal (95% CI) 627 315 17.0 % 2.53 [ 0.00, 5.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 589 0.18 (9.98) 582 -0.96 (9.98) 83.0 % 1.14 [ 0.00, 2.28 ]
Subtotal (95% CI) 589 582 83.0 % 1.14 [ 0.00, 2.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
Total (95% CI) 1216 897 100.0 % 1.38 [ 0.33, 2.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0096)
Test for subgroup differences: Chi2 = 0.96, df = 1 (P = 0.33), I2 =0.0%
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Analysis 2.1. Comparison 2 Secondary Efficacy Outcome (Natalizumab vs Control), Outcome 1 Change in
Well-being (VAS) at 2 yrs.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 2 Secondary Efficacy Outcome (Natalizumab vs Control)
Outcome: 1 Change in Well-being (VAS) at 2 yrs





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Natalizumab vs Placebo
AFFIRM 2006 627 0.2 (34.29) 315 -6.2 (34.29) 100.0 % 6.40 [ 1.76, 11.04 ]
Total (95% CI) 627 315 100.0 % 6.40 [ 1.76, 11.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0069)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Secondary Efficacy Outcome (Natalizumab vs Control), Outcome 2 Gd-
enhacing lesion (at least one) at 2 yrs.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 2 Secondary Efficacy Outcome (Natalizumab vs Control)
Outcome: 2 Gd-enhacing lesion (at least one) at 2 yrs








1 Natalizumab vs Placebo
AFFIRM 2006 22/627 102/315 50.3 % 0.11 [ 0.07, 0.17 ]
Subtotal (95% CI) 627 315 50.3 % 0.11 [ 0.07, 0.17 ]
Total events: 22 (Experimental), 102 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 9.89 (P < 0.00001)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 21/589 147/582 49.7 % 0.14 [ 0.09, 0.22 ]
Subtotal (95% CI) 589 582 49.7 % 0.14 [ 0.09, 0.22 ]
Total events: 21 (Experimental), 147 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 8.67 (P < 0.00001)
Total (95% CI) 1216 897 100.0 % 0.12 [ 0.09, 0.17 ]
Total events: 43 (Experimental), 249 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 13.13 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.69, df = 1 (P = 0.41), I2 =0.0%
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Analysis 2.3. Comparison 2 Secondary Efficacy Outcome (Natalizumab vs Control), Outcome 3 Change of
MRI T2 total lesion load at 2 yrs.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 2 Secondary Efficacy Outcome (Natalizumab vs Control)
Outcome: 3 Change of MRI T2 total lesion load at 2 yrs





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Natalizumab vs Placebo
AFFIRM 2006 576 -905.4 (12781.2) 279 2890.8 (15068.4) 100.0 % -3796.20 [ -5849.43, -1742.97 ]
Total (95% CI) 576 279 100.0 % -3796.20 [ -5849.43, -1742.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.62 (P = 0.00029)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Primary Safety Outcome (Natalizumab vs Control), Outcome 1 N of pts with
Severe AE over 2 yrs.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 3 Primary Safety Outcome (Natalizumab vs Control)
Outcome: 1 N of pts with Severe AE over 2 yrs








1 Natalizumab vs Placebo
AFFIRM 2006 144/627 84/312 30.2 % 0.85 [ 0.68, 1.08 ]
Subtotal (95% CI) 627 312 30.2 % 0.85 [ 0.68, 1.08 ]
Total events: 144 (Experimental), 84 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 206/589 215/582 69.8 % 0.95 [ 0.81, 1.10 ]
Subtotal (95% CI) 589 582 69.8 % 0.95 [ 0.81, 1.10 ]
Total events: 206 (Experimental), 215 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 1216 894 100.0 % 0.92 [ 0.81, 1.04 ]
Total events: 350 (Experimental), 299 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
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Analysis 3.2. Comparison 3 Primary Safety Outcome (Natalizumab vs Control), Outcome 2 N of pts with
Serious AE (irrespective of treatment duration).
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 3 Primary Safety Outcome (Natalizumab vs Control)
Outcome: 2 N of pts with Serious AE (irrespective of treatment duration)








1 Natalizumab vs Placebo
AFFIRM 2006 119/627 75/312 45.2 % 0.79 [ 0.61, 1.02 ]
Subtotal (95% CI) 627 312 45.2 % 0.79 [ 0.61, 1.02 ]
Total events: 119 (Experimental), 75 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 107/589 122/582 54.2 % 0.87 [ 0.69, 1.09 ]
Subtotal (95% CI) 589 582 54.2 % 0.87 [ 0.69, 1.09 ]
Total events: 107 (Experimental), 122 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
3 Natalizumab + GA vs GA
GLANCE 2009 1/55 2/55 0.5 % 0.50 [ 0.05, 5.36 ]
Subtotal (95% CI) 55 55 0.5 % 0.50 [ 0.05, 5.36 ]
Total events: 1 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 1271 949 100.0 % 0.83 [ 0.70, 0.98 ]
Total events: 227 (Experimental), 199 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Chi2 = 0.45, df = 2 (P = 0.80), I2 =0.0%
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Analysis 3.3. Comparison 3 Primary Safety Outcome (Natalizumab vs Control), Outcome 3 N of pts with
serious AE (irrespective of treatment duration - MS relapses excluded).
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 3 Primary Safety Outcome (Natalizumab vs Control)
Outcome: 3 N of pts with serious AE (irrespective of treatment duration - MS relapses excluded)








1 Natalizumab vs Placebo
AFFIRM 2006 81/627 34/312 38.8 % 1.19 [ 0.81, 1.73 ]
Subtotal (95% CI) 627 312 38.8 % 1.19 [ 0.81, 1.73 ]
Total events: 81 (Experimental), 34 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.38)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 78/589 70/582 60.5 % 1.10 [ 0.81, 1.49 ]
Subtotal (95% CI) 589 582 60.5 % 1.10 [ 0.81, 1.49 ]
Total events: 78 (Experimental), 70 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
3 Natalizumab + GA vs GA
GLANCE 2009 1/55 1/55 0.7 % 1.00 [ 0.06, 15.59 ]
Subtotal (95% CI) 55 55 0.7 % 1.00 [ 0.06, 15.59 ]
Total events: 1 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1271 949 100.0 % 1.13 [ 0.90, 1.43 ]
Total events: 160 (Experimental), 105 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.10, df = 2 (P = 0.95), I2 =0.0%
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Analysis 4.1. Comparison 4 Secondary Safety Outcome (Natalizumab vs Control), Outcome 1 N of pts with
at least one AE (irrespective of treatment duration).
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 4 Secondary Safety Outcome (Natalizumab vs Control)
Outcome: 1 N of pts with at least one AE (irrespective of treatment duration)








1 Natalizumab vs Placebo
AFFIRM 2006 596/627 300/312 11.0 % 0.99 [ 0.96, 1.02 ]
Subtotal (95% CI) 627 312 11.0 % 0.99 [ 0.96, 1.02 ]
Total events: 596 (Experimental), 300 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 584/589 578/582 88.2 % 1.00 [ 0.99, 1.01 ]
Subtotal (95% CI) 589 582 88.2 % 1.00 [ 0.99, 1.01 ]
Total events: 584 (Experimental), 578 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
3 Natalizumab + GA vs GA
GLANCE 2009 50/55 51/55 0.7 % 0.98 [ 0.88, 1.10 ]
Subtotal (95% CI) 55 55 0.7 % 0.98 [ 0.88, 1.10 ]
Total events: 50 (Experimental), 51 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI) 1271 949 100.0 % 1.00 [ 0.99, 1.01 ]
Total events: 1230 (Experimental), 929 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Chi2 = 0.50, df = 2 (P = 0.78), I2 =0.0%
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Analysis 4.2. Comparison 4 Secondary Safety Outcome (Natalizumab vs Control), Outcome 2 Treatment
Discontinuation caused by AE (irrespective of treatment duration).
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 4 Secondary Safety Outcome (Natalizumab vs Control)
Outcome: 2 Treatment Discontinuation caused by AE (irrespective of treatment duration)








1 Natalizumab vs Placebo
AFFIRM 2006 38/627 12/312 27.5 % 1.58 [ 0.84, 2.97 ]
Subtotal (95% CI) 627 312 27.5 % 1.58 [ 0.84, 2.97 ]
Total events: 38 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 46/589 45/582 71.1 % 1.01 [ 0.68, 1.50 ]
Subtotal (95% CI) 589 582 71.1 % 1.01 [ 0.68, 1.50 ]
Total events: 46 (Experimental), 45 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 Natalizumab + GA vs GA
GLANCE 2009 1/55 1/55 1.5 % 1.00 [ 0.06, 15.59 ]
Subtotal (95% CI) 55 55 1.5 % 1.00 [ 0.06, 15.59 ]
Total events: 1 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1271 949 100.0 % 1.14 [ 0.82, 1.59 ]
Total events: 85 (Experimental), 58 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.37, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Chi2 = 1.37, df = 2 (P = 0.50), I2 =0.0%
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Analysis 5.1. Comparison 5 Adverse Event Analysis, Outcome 1 Headache.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 1 Headache








1 Natalizumab vs Placebo
AFFIRM 2006 238/627 103/312 30.5 % 1.15 [ 0.95, 1.39 ]
Subtotal (95% CI) 627 312 30.5 % 1.15 [ 0.95, 1.39 ]
Total events: 238 (Experimental), 103 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
2 Natalizumab IFN vs IFN
SENTINEL 2006 271/589 256/582 66.4 % 1.05 [ 0.92, 1.19 ]
Subtotal (95% CI) 589 582 66.4 % 1.05 [ 0.92, 1.19 ]
Total events: 271 (Experimental), 256 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
3 Natalizumab + GA vs GA
GLANCE 2009 17/55 15/55 3.1 % 1.13 [ 0.63, 2.03 ]
Subtotal (95% CI) 55 55 3.1 % 1.13 [ 0.63, 2.03 ]
Total events: 17 (Experimental), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Total (95% CI) 1271 949 100.0 % 1.08 [ 0.97, 1.20 ]
Total events: 526 (Experimental), 374 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 0.70, df = 2 (P = 0.70), I2 =0.0%
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Analysis 5.2. Comparison 5 Adverse Event Analysis, Outcome 2 Pain in arms or legs - Arthralgia.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 2 Pain in arms or legs - Arthralgia
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Natalizumab vs Placebo
AFFIRM 2006 119/627 44/312 32.2 % 1.35 [ 0.98, 1.85 ]
Subtotal (95% CI) 627 312 32.2 % 1.35 [ 0.98, 1.85 ]
Total events: 119 (Experimental), 44 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 130/589 122/582 67.3 % 1.05 [ 0.85, 1.31 ]
Subtotal (95% CI) 589 582 67.3 % 1.05 [ 0.85, 1.31 ]
Total events: 130 (Experimental), 122 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
3 Natalizumab + GA vs GA
GLANCE 2009 5/55 1/55 0.5 % 5.00 [ 0.60, 41.42 ]
Subtotal (95% CI) 55 55 0.5 % 5.00 [ 0.60, 41.42 ]
Total events: 5 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Total (95% CI) 1271 949 100.0 % 1.17 [ 0.98, 1.40 ]
Total events: 254 (Experimental), 167 (Control)
Heterogeneity: Chi2 = 3.44, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.70 (P = 0.088)
Test for subgroup differences: Chi2 = 3.42, df = 2 (P = 0.18), I2 =41%
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Analysis 5.3. Comparison 5 Adverse Event Analysis, Outcome 3 Depression.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 3 Depression








1 Natalizumab vs Placebo
AFFIRM 2006 119/627 50/312 37.1 % 1.18 [ 0.88, 1.60 ]
Subtotal (95% CI) 627 312 37.1 % 1.18 [ 0.88, 1.60 ]
Total events: 119 (Experimental), 50 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 124/589 105/582 61.8 % 1.17 [ 0.92, 1.47 ]
Subtotal (95% CI) 589 582 61.8 % 1.17 [ 0.92, 1.47 ]
Total events: 124 (Experimental), 105 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
3 Natalizumab + GA vs GA
GLANCE 2009 3/55 2/55 1.1 % 1.50 [ 0.26, 8.63 ]
Subtotal (95% CI) 55 55 1.1 % 1.50 [ 0.26, 8.63 ]
Total events: 3 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 1271 949 100.0 % 1.18 [ 0.98, 1.41 ]
Total events: 246 (Experimental), 157 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Chi2 = 0.08, df = 2 (P = 0.96), I2 =0.0%
0.01 0.1 1 10 100
Favours Natalizumab Favours Control
52Natalizumab for relapsing remitting multiple sclerosis (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.4. Comparison 5 Adverse Event Analysis, Outcome 4 Anxiety.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 4 Anxiety








1 Natalizumab + IFN vs IFN
SENTINEL 2006 71/589 47/582 100.0 % 1.49 [ 1.05, 2.12 ]
Total (95% CI) 589 582 100.0 % 1.49 [ 1.05, 2.12 ]
Total events: 71 (Experimental), 47 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Adverse Event Analysis, Outcome 5 Insomnia.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 5 Insomnia








1 Natalizumab + IFN vs IFN
SENTINEL 2006 106/589 99/582 100.0 % 1.06 [ 0.82, 1.36 ]
Total (95% CI) 589 582 100.0 % 1.06 [ 0.82, 1.36 ]
Total events: 106 (Experimental), 99 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 Adverse Event Analysis, Outcome 6 Influenza Like Illness.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 6 Influenza Like Illness








1 Natalizumab + IFN vs IFN
SENTINEL 2006 118/589 111/582 100.0 % 1.05 [ 0.83, 1.33 ]
Total (95% CI) 589 582 100.0 % 1.05 [ 0.83, 1.33 ]
Total events: 118 (Experimental), 111 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Adverse Event Analysis, Outcome 7 Nasopharyngitis.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 7 Nasopharyngitis
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Natalizumab + IFN vs IFN
SENTINEL 2006 230/589 204/582 94.9 % 1.11 [ 0.96, 1.29 ]
Subtotal (95% CI) 589 582 94.9 % 1.11 [ 0.96, 1.29 ]
Total events: 230 (Experimental), 204 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 Natalizumab + GA vs GA
GLANCE 2009 7/55 11/55 5.1 % 0.64 [ 0.27, 1.52 ]
Subtotal (95% CI) 55 55 5.1 % 0.64 [ 0.27, 1.52 ]
Total events: 7 (Experimental), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 644 637 100.0 % 1.09 [ 0.94, 1.26 ]
Total events: 237 (Experimental), 215 (Control)
Heterogeneity: Chi2 = 1.55, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Chi2 = 1.54, df = 1 (P = 0.21), I2 =35%
0.5 0.7 1 1.5 2
Favours Natalizumab Favours Control
55Natalizumab for relapsing remitting multiple sclerosis (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.8. Comparison 5 Adverse Event Analysis, Outcome 8 Pharyngitis.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 8 Pharyngitis








1 Natalizumab vs Placebo
AFFIRM 2006 75/627 31/312 58.2 % 1.20 [ 0.81, 1.79 ]
Subtotal (95% CI) 627 312 58.2 % 1.20 [ 0.81, 1.79 ]
Total events: 75 (Experimental), 31 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 41/589 23/582 41.8 % 1.76 [ 1.07, 2.90 ]
Subtotal (95% CI) 589 582 41.8 % 1.76 [ 1.07, 2.90 ]
Total events: 41 (Experimental), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
Total (95% CI) 1216 894 100.0 % 1.41 [ 0.98, 2.04 ]
Total events: 116 (Experimental), 54 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.38, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Chi2 = 1.38, df = 1 (P = 0.24), I2 =27%
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Analysis 5.9. Comparison 5 Adverse Event Analysis, Outcome 9 Sinusitis.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 9 Sinusitis








1 Natalizumab + IFN vs IFN
SENTINEL 2006 106/589 87/582 89.2 % 1.20 [ 0.93, 1.56 ]
Subtotal (95% CI) 589 582 89.2 % 1.20 [ 0.93, 1.56 ]
Total events: 106 (Experimental), 87 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 Natalizumab + GA vs GA
GLANCE 2009 9/55 4/55 10.8 % 2.25 [ 0.74, 6.87 ]
Subtotal (95% CI) 55 55 10.8 % 2.25 [ 0.74, 6.87 ]
Total events: 9 (Experimental), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
Total (95% CI) 644 637 100.0 % 1.29 [ 0.88, 1.88 ]
Total events: 115 (Experimental), 91 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.14, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Chi2 = 1.14, df = 1 (P = 0.29), I2 =12%
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Analysis 5.10. Comparison 5 Adverse Event Analysis, Outcome 10 Sinus Congestion.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 10 Sinus Congestion








1 Natalizumab + IFN vs IFN
SENTINEL 2006 35/589 17/582 100.0 % 2.03 [ 1.15, 3.59 ]
Total (95% CI) 589 582 100.0 % 2.03 [ 1.15, 3.59 ]
Total events: 35 (Experimental), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 5.11. Comparison 5 Adverse Event Analysis, Outcome 11 Sinus Headache.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 11 Sinus Headache








1 Natalizumab + IFN vs IFN
SENTINEL 2006 29/589 17/582 100.0 % 1.69 [ 0.94, 3.03 ]
Total (95% CI) 589 582 100.0 % 1.69 [ 0.94, 3.03 ]
Total events: 29 (Experimental), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Not applicable
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Analysis 5.12. Comparison 5 Adverse Event Analysis, Outcome 12 Upper Respiratory Infection.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 12 Upper Respiratory Infection








1 Natalizumab vs Placebo
AFFIRM 2006 163/627 81/312 72.8 % 1.00 [ 0.80, 1.26 ]
Subtotal (95% CI) 627 312 72.8 % 1.00 [ 0.80, 1.26 ]
Total events: 163 (Experimental), 81 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 47/589 41/582 23.6 % 1.13 [ 0.76, 1.69 ]
Subtotal (95% CI) 589 582 23.6 % 1.13 [ 0.76, 1.69 ]
Total events: 47 (Experimental), 41 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Natalizumab + GA vs GA
GLANCE 2009 9/55 5/55 3.6 % 1.80 [ 0.64, 5.03 ]
Subtotal (95% CI) 55 55 3.6 % 1.80 [ 0.64, 5.03 ]
Total events: 9 (Experimental), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 1271 949 100.0 % 1.05 [ 0.87, 1.28 ]
Total events: 219 (Experimental), 127 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 1.36, df = 2 (P = 0.51), I2 =0.0%
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Analysis 5.13. Comparison 5 Adverse Event Analysis, Outcome 13 Influenza.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 13 Influenza








1 Natalizumab + IFN vs IFN
SENTINEL 2006 100/589 87/582 100.0 % 1.14 [ 0.87, 1.48 ]
Total (95% CI) 589 582 100.0 % 1.14 [ 0.87, 1.48 ]
Total events: 100 (Experimental), 87 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 5.14. Comparison 5 Adverse Event Analysis, Outcome 14 Cough.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 14 Cough








1 Natalizumab + IFN vs IFN
SENTINEL 2006 65/589 52/582 100.0 % 1.24 [ 0.87, 1.75 ]
Total (95% CI) 589 582 100.0 % 1.24 [ 0.87, 1.75 ]
Total events: 65 (Experimental), 52 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 5.15. Comparison 5 Adverse Event Analysis, Outcome 15 Diarrhea.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 15 Diarrhea








1 Natalizumab + IFN vs IFN
SENTINEL 2006 112/589 93/582 100.0 % 1.19 [ 0.93, 1.53 ]
Total (95% CI) 589 582 100.0 % 1.19 [ 0.93, 1.53 ]
Total events: 112 (Experimental), 93 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 5.16. Comparison 5 Adverse Event Analysis, Outcome 16 Nausea.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 16 Nausea








1 Natalizumab + IFN vs IFN
SENTINEL 2006 100/589 87/582 91.7 % 1.14 [ 0.87, 1.48 ]
Subtotal (95% CI) 589 582 91.7 % 1.14 [ 0.87, 1.48 ]
Total events: 100 (Experimental), 87 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
2 Natalizumab + GA vs GA
GLANCE 2009 9/55 8/55 8.3 % 1.13 [ 0.47, 2.70 ]
Subtotal (95% CI) 55 55 8.3 % 1.13 [ 0.47, 2.70 ]
Total events: 9 (Experimental), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI) 644 637 100.0 % 1.13 [ 0.88, 1.46 ]
Total events: 109 (Experimental), 95 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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Analysis 5.17. Comparison 5 Adverse Event Analysis, Outcome 17 Vomiting.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 17 Vomiting








1 Natalizumab + IFN vs IFN
SENTINEL 2006 41/589 29/582 100.0 % 1.40 [ 0.88, 2.22 ]
Total (95% CI) 589 582 100.0 % 1.40 [ 0.88, 2.22 ]
Total events: 41 (Experimental), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 5.18. Comparison 5 Adverse Event Analysis, Outcome 18 Abdominal Pain or Discomfort.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 18 Abdominal Pain or Discomfort








1 Natalizumab vs Placebo
AFFIRM 2006 69/627 31/312 58.7 % 1.11 [ 0.74, 1.65 ]
Subtotal (95% CI) 627 312 58.7 % 1.11 [ 0.74, 1.65 ]
Total events: 69 (Experimental), 31 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 35/589 29/582 41.3 % 1.19 [ 0.74, 1.92 ]
Subtotal (95% CI) 589 582 41.3 % 1.19 [ 0.74, 1.92 ]
Total events: 35 (Experimental), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 1216 894 100.0 % 1.14 [ 0.84, 1.55 ]
Total events: 104 (Experimental), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 5.19. Comparison 5 Adverse Event Analysis, Outcome 19 Muscle Cramp.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 19 Muscle Cramp








1 Natalizumab + IFN vs IFN
SENTINEL 2006 35/589 29/582 100.0 % 1.19 [ 0.74, 1.92 ]
Total (95% CI) 589 582 100.0 % 1.19 [ 0.74, 1.92 ]
Total events: 35 (Experimental), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 5.20. Comparison 5 Adverse Event Analysis, Outcome 20 Myalgia.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 20 Myalgia








1 Natalizumab + IFN vs IFN
SENTINEL 2006 77/589 58/582 100.0 % 1.31 [ 0.95, 1.81 ]
Total (95% CI) 589 582 100.0 % 1.31 [ 0.95, 1.81 ]
Total events: 77 (Experimental), 58 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Not applicable
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Analysis 5.21. Comparison 5 Adverse Event Analysis, Outcome 21 Seasonal Allergy.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 21 Seasonal Allergy








1 Natalizumab + IFN vs IFN
SENTINEL 2006 35/589 23/582 100.0 % 1.50 [ 0.90, 2.51 ]
Total (95% CI) 589 582 100.0 % 1.50 [ 0.90, 2.51 ]
Total events: 35 (Experimental), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 5.22. Comparison 5 Adverse Event Analysis, Outcome 22 Peripheral Edema.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 22 Peripheral Edema








1 Natalizumab + IFN vs IFN
SENTINEL 2006 29/589 6/582 100.0 % 4.78 [ 2.00, 11.42 ]
Total (95% CI) 589 582 100.0 % 4.78 [ 2.00, 11.42 ]
Total events: 29 (Experimental), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Not applicable
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Analysis 5.23. Comparison 5 Adverse Event Analysis, Outcome 23 Tremor.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 23 Tremor








1 Natalizumab vs Placebo
AFFIRM 2006 19/627 9/312 36.1 % 1.05 [ 0.48, 2.29 ]
Subtotal (95% CI) 627 312 36.1 % 1.05 [ 0.48, 2.29 ]
Total events: 19 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 29/589 17/582 63.9 % 1.69 [ 0.94, 3.03 ]
Subtotal (95% CI) 589 582 63.9 % 1.69 [ 0.94, 3.03 ]
Total events: 29 (Experimental), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 1216 894 100.0 % 1.42 [ 0.89, 2.27 ]
Total events: 48 (Experimental), 26 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 0.90, df = 1 (P = 0.34), I2 =0.0%
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Analysis 5.24. Comparison 5 Adverse Event Analysis, Outcome 24 Flushing.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 24 Flushing








1 Natalizumab GA vs GA
GLANCE 2009 6/55 1/55 100.0 % 6.00 [ 0.75, 48.21 ]
Total (95% CI) 55 55 100.0 % 6.00 [ 0.75, 48.21 ]
Total events: 6 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.092)
Test for subgroup differences: Not applicable
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Analysis 5.25. Comparison 5 Adverse Event Analysis, Outcome 25 Fatigue - Myasthenia.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 25 Fatigue - Myasthenia








1 Natalizumab vs Placebo
AFFIRM 2006 169/627 66/312 100.0 % 1.27 [ 0.99, 1.64 ]
Total (95% CI) 627 312 100.0 % 1.27 [ 0.99, 1.64 ]
Total events: 169 (Experimental), 66 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
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Analysis 5.26. Comparison 5 Adverse Event Analysis, Outcome 26 Urinary Urgency / Frequency.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 26 Urinary Urgency / Frequency








1 Natalizumab vs Placebo
AFFIRM 2006 56/627 22/312 100.0 % 1.27 [ 0.79, 2.03 ]
Total (95% CI) 627 312 100.0 % 1.27 [ 0.79, 2.03 ]
Total events: 56 (Natalizumab), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 5.27. Comparison 5 Adverse Event Analysis, Outcome 27 Hypersensitivity reactions.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 27 Hypersensitivity reactions








1 Natalizumab vs Placebo
AFFIRM 2006 25/627 0/312 29.7 % 25.42 [ 1.55, 416.15 ]
Subtotal (95% CI) 627 312 29.7 % 25.42 [ 1.55, 416.15 ]
Total events: 25 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 11/589 2/582 42.4 % 5.43 [ 1.21, 24.41 ]
Subtotal (95% CI) 589 582 42.4 % 5.43 [ 1.21, 24.41 ]
Total events: 11 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
3 Natalizumab GA vs GA
GLANCE 2009 0/55 2/55 27.9 % 0.20 [ 0.01, 4.07 ]
Subtotal (95% CI) 55 55 27.9 % 0.20 [ 0.01, 4.07 ]
Total events: 0 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.30)
Total (95% CI) 1271 949 100.0 % 3.43 [ 0.33, 36.07 ]
Total events: 36 (Experimental), 4 (Control)
Heterogeneity: Tau2 = 2.81; Chi2 = 5.79, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 5.63, df = 2 (P = 0.06), I2 =64%
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Analysis 5.28. Comparison 5 Adverse Event Analysis, Outcome 28 Chest Discomfort.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 28 Chest Discomfort








1 Natalizumab vs Placebo
AFFIRM 2006 31/627 9/312 100.0 % 1.71 [ 0.83, 3.56 ]
Total (95% CI) 627 312 100.0 % 1.71 [ 0.83, 3.56 ]
Total events: 31 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 5.29. Comparison 5 Adverse Event Analysis, Outcome 29 Local Bleeding.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 29 Local Bleeding








1 Natalizumab vs Placebo
AFFIRM 2006 19/627 6/312 100.0 % 1.58 [ 0.64, 3.91 ]
Total (95% CI) 627 312 100.0 % 1.58 [ 0.64, 3.91 ]
Total events: 19 (Experimental), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 5.30. Comparison 5 Adverse Event Analysis, Outcome 30 Rigors.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 30 Rigors








1 Natalizumab vs Placebo
AFFIRM 2006 19/627 3/312 85.5 % 3.15 [ 0.94, 10.57 ]
Subtotal (95% CI) 627 312 85.5 % 3.15 [ 0.94, 10.57 ]
Total events: 19 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
2 Natalizumab GA vs GA
GLANCE 2009 3/55 0/55 14.5 % 7.00 [ 0.37, 132.40 ]
Subtotal (95% CI) 55 55 14.5 % 7.00 [ 0.37, 132.40 ]
Total events: 3 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 682 367 100.0 % 3.54 [ 1.16, 10.83 ]
Total events: 22 (Experimental), 3 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
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Analysis 5.31. Comparison 5 Adverse Event Analysis, Outcome 31 Syncope.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 31 Syncope








1 Natalizumab vs Placebo
AFFIRM 2006 19/627 9/312 100.0 % 1.05 [ 0.48, 2.29 ]
Total (95% CI) 627 312 100.0 % 1.05 [ 0.48, 2.29 ]
Total events: 19 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Natalizumab Favours Control
74Natalizumab for relapsing remitting multiple sclerosis (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.32. Comparison 5 Adverse Event Analysis, Outcome 32 Urinary Infection.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 32 Urinary Infection








1 Natalizumab vs Placebo
AFFIRM 2006 125/627 53/312 80.3 % 1.17 [ 0.88, 1.57 ]
Subtotal (95% CI) 627 312 80.3 % 1.17 [ 0.88, 1.57 ]
Total events: 125 (Experimental), 53 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Natalizumab GA vs GA
GLANCE 2009 3/55 6/55 19.7 % 0.50 [ 0.13, 1.90 ]
Subtotal (95% CI) 55 55 19.7 % 0.50 [ 0.13, 1.90 ]
Total events: 3 (Experimental), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 682 367 100.0 % 0.99 [ 0.51, 1.93 ]
Total events: 128 (Experimental), 59 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 1.50, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 1.50, df = 1 (P = 0.22), I2 =33%
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Analysis 5.33. Comparison 5 Adverse Event Analysis, Outcome 33 Lower Respiratory Infection.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 33 Lower Respiratory Infection








1 Natalizumab vs Placebo
AFFIRM 2006 107/627 50/312 100.0 % 1.06 [ 0.78, 1.45 ]
Total (95% CI) 627 312 100.0 % 1.06 [ 0.78, 1.45 ]
Total events: 107 (Experimental), 50 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 5.34. Comparison 5 Adverse Event Analysis, Outcome 34 Tonsillitis.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 34 Tonsillitis








1 Natalizumab vs Placebo
AFFIRM 2006 44/627 16/312 100.0 % 1.37 [ 0.78, 2.39 ]
Total (95% CI) 627 312 100.0 % 1.37 [ 0.78, 2.39 ]
Total events: 44 (Experimental), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 5.35. Comparison 5 Adverse Event Analysis, Outcome 35 Gastroenteritis.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 35 Gastroenteritis








1 Natalizumab vs Placebo
AFFIRM 2006 69/627 28/312 100.0 % 1.23 [ 0.81, 1.86 ]
Total (95% CI) 627 312 100.0 % 1.23 [ 0.81, 1.86 ]
Total events: 69 (Experimental), 28 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 5.36. Comparison 5 Adverse Event Analysis, Outcome 36 Vaginitis.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 36 Vaginitis








1 Natalizumab vs Placebo
AFFIRM 2006 63/627 19/312 100.0 % 1.65 [ 1.01, 2.71 ]
Total (95% CI) 627 312 100.0 % 1.65 [ 1.01, 2.71 ]
Total events: 63 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 5.37. Comparison 5 Adverse Event Analysis, Outcome 37 Menstrual disorders.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 37 Menstrual disorders








1 Natalizumab vs Placebo
AFFIRM 2006 57/627 15/312 100.0 % 1.89 [ 1.09, 3.29 ]
Total (95% CI) 627 312 100.0 % 1.89 [ 1.09, 3.29 ]
Total events: 57 (Experimental), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 5.38. Comparison 5 Adverse Event Analysis, Outcome 38 Skin Rash.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 38 Skin Rash








1 Natalizumab vs Placebo
AFFIRM 2006 69/627 28/312 71.2 % 1.23 [ 0.81, 1.86 ]
Subtotal (95% CI) 627 312 71.2 % 1.23 [ 0.81, 1.86 ]
Total events: 69 (Experimental), 28 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
2 Natalizumab + GA vs GA
GLANCE 2009 6/55 1/55 28.8 % 6.00 [ 0.75, 48.21 ]
Subtotal (95% CI) 55 55 28.8 % 6.00 [ 0.75, 48.21 ]
Total events: 6 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.092)
Total (95% CI) 682 367 100.0 % 1.94 [ 0.47, 7.99 ]
Total events: 75 (Experimental), 29 (Control)
Heterogeneity: Tau2 = 0.69; Chi2 = 2.17, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 2.14, df = 1 (P = 0.14), I2 =53%
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Analysis 5.39. Comparison 5 Adverse Event Analysis, Outcome 39 Dermatitis.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 39 Dermatitis








1 Natalizumab vs Placebo
AFFIRM 2006 44/627 12/312 86.0 % 1.82 [ 0.98, 3.40 ]
Subtotal (95% CI) 627 312 86.0 % 1.82 [ 0.98, 3.40 ]
Total events: 44 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
2 Natalizumab + GA vs GA
GLANCE 2009 6/55 1/55 14.0 % 6.00 [ 0.75, 48.21 ]
Subtotal (95% CI) 55 55 14.0 % 6.00 [ 0.75, 48.21 ]
Total events: 6 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.092)
Total (95% CI) 682 367 100.0 % 2.15 [ 0.96, 4.85 ]
Total events: 50 (Experimental), 13 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Chi2 = 1.15, df = 1 (P = 0.28), I2 =13%
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Analysis 5.40. Comparison 5 Adverse Event Analysis, Outcome 40 Pruritus.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 40 Pruritus








1 Natalizumab vs Placebo
AFFIRM 2006 25/627 6/312 100.0 % 2.07 [ 0.86, 5.00 ]
Total (95% CI) 627 312 100.0 % 2.07 [ 0.86, 5.00 ]
Total events: 25 (Experimental), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 5.41. Comparison 5 Adverse Event Analysis, Outcome 41 Vertigo.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 41 Vertigo








1 Natalizumab vs Placebo
AFFIRM 2006 38/627 16/312 100.0 % 1.18 [ 0.67, 2.09 ]
Total (95% CI) 627 312 100.0 % 1.18 [ 0.67, 2.09 ]
Total events: 38 (Experimental), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 5.42. Comparison 5 Adverse Event Analysis, Outcome 42 Infection.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 42 Infection








1 Natalizumab vs Placebo
AFFIRM 2006 495/627 246/312 36.1 % 1.00 [ 0.93, 1.07 ]
Subtotal (95% CI) 627 312 36.1 % 1.00 [ 0.93, 1.07 ]
Total events: 495 (Experimental), 246 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 489/589 471/582 61.7 % 1.03 [ 0.97, 1.08 ]
Subtotal (95% CI) 589 582 61.7 % 1.03 [ 0.97, 1.08 ]
Total events: 489 (Experimental), 471 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
3 Natalizumab + GA vs GA
GLANCE 2009 33/55 36/55 2.1 % 0.92 [ 0.69, 1.22 ]
Subtotal (95% CI) 55 55 2.1 % 0.92 [ 0.69, 1.22 ]
Total events: 33 (Experimental), 36 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Total (95% CI) 1271 949 100.0 % 1.01 [ 0.97, 1.06 ]
Total events: 1017 (Experimental), 753 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 0.77, df = 2 (P = 0.68), I2 =0.0%
0.01 0.1 1 10 100
Favours Natalizumab Favours Control
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Analysis 5.43. Comparison 5 Adverse Event Analysis, Outcome 43 Infusion reactions.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 43 Infusion reactions








1 Natalizumab vs Placebo
AFFIRM 2006 148/627 55/312 36.9 % 1.34 [ 1.01, 1.77 ]
Subtotal (95% CI) 627 312 36.9 % 1.34 [ 1.01, 1.77 ]
Total events: 148 (Experimental), 55 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.040)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 141/589 116/582 60.4 % 1.20 [ 0.97, 1.49 ]
Subtotal (95% CI) 589 582 60.4 % 1.20 [ 0.97, 1.49 ]
Total events: 141 (Experimental), 116 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.098)
3 Natalizumab + GA vs GA
GLANCE 2009 6/55 7/55 2.7 % 0.86 [ 0.31, 2.39 ]
Subtotal (95% CI) 55 55 2.7 % 0.86 [ 0.31, 2.39 ]
Total events: 6 (Experimental), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 1271 949 100.0 % 1.24 [ 1.05, 1.47 ]
Total events: 295 (Experimental), 178 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Chi2 = 0.87, df = 2 (P = 0.65), I2 =0.0%
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Analysis 5.44. Comparison 5 Adverse Event Analysis, Outcome 44 Back Pain.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 44 Back Pain








1 Natalizumab +GA vs GA
GLANCE 2009 9/55 4/55 100.0 % 2.25 [ 0.74, 6.87 ]
Total (95% CI) 55 55 100.0 % 2.25 [ 0.74, 6.87 ]
Total events: 9 (Experimental), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 5.45. Comparison 5 Adverse Event Analysis, Outcome 45 Fall.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 45 Fall








AFFIRM 2006 5/627 2/312 64.5 % 1.24 [ 0.24, 6.38 ]
SENTINEL 2006 5/589 0/582 35.5 % 10.87 [ 0.60, 196.13 ]
Total (95% CI) 1216 894 100.0 % 2.69 [ 0.32, 22.39 ]
Total events: 10 (Experimental), 2 (Control)
Heterogeneity: Tau2 = 1.12; Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Favours experimental Favours control
84Natalizumab for relapsing remitting multiple sclerosis (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.46. Comparison 5 Adverse Event Analysis, Outcome 46 Neoplasms.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 46 Neoplasms








1 Natalizumab vs Placebo
AFFIRM 2006 5/627 1/312 2.49 [ 0.29, 21.20 ]
Subtotal (95% CI) 627 312 2.49 [ 0.29, 21.20 ]
Total events: 5 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 6/589 12/582 0.49 [ 0.19, 1.31 ]
Subtotal (95% CI) 589 582 0.49 [ 0.19, 1.31 ]
Total events: 6 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
3 Natalizumab + GA vs GA
GLANCE 2009 0/55 0/55 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 55 55 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 1271 949 0.83 [ 0.19, 3.66 ]
Total events: 11 (Experimental), 13 (Control)
Heterogeneity: Tau2 = 0.60; Chi2 = 1.83, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 1.81, df = 1 (P = 0.18), I2 =45%
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Analysis 5.47. Comparison 5 Adverse Event Analysis, Outcome 47 Abnormal liver function tests.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 47 Abnormal liver function tests








1 Natalizumab vs Placebo
AFFIRM 2006 31/627 12/312 100.0 % 1.29 [ 0.67, 2.47 ]
Total (95% CI) 627 312 100.0 % 1.29 [ 0.67, 2.47 ]
Total events: 31 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 5.48. Comparison 5 Adverse Event Analysis, Outcome 48 Death.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 48 Death








1 Natalizumab vs Placebo
AFFIRM 2006 2/627 0/312 2.49 [ 0.12, 51.75 ]
Subtotal (95% CI) 627 312 2.49 [ 0.12, 51.75 ]
Total events: 2 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 Natalizumab + GA vs GA
GLANCE 2009 0/55 0/55 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 55 55 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
3 Natalizumab + IFN vs IFN
SENTINEL 2006 1/589 2/582 0.49 [ 0.04, 5.43 ]
Subtotal (95% CI) 589 582 0.49 [ 0.04, 5.43 ]
Total events: 1 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 1271 949 0.92 [ 0.14, 6.04 ]
Total events: 3 (Experimental), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 0.67, df = 1 (P = 0.41), I2 =0.0%
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Analysis 5.49. Comparison 5 Adverse Event Analysis, Outcome 49 MS relapse as a serious AE.
Review: Natalizumab for relapsing remitting multiple sclerosis
Comparison: 5 Adverse Event Analysis
Outcome: 49 MS relapse as a serious AE








1 Natalizumab vs Placebo
AFFIRM 2006 38/627 41/312 51.8 % 0.46 [ 0.30, 0.70 ]
Subtotal (95% CI) 627 312 51.8 % 0.46 [ 0.30, 0.70 ]
Total events: 38 (Experimental), 41 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.61 (P = 0.00030)
2 Natalizumab + IFN vs IFN
SENTINEL 2006 29/589 52/582 47.3 % 0.55 [ 0.36, 0.86 ]
Subtotal (95% CI) 589 582 47.3 % 0.55 [ 0.36, 0.86 ]
Total events: 29 (Experimental), 52 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0079)
3 Natalizumab + GA vs GA
GLANCE 2009 0/55 1/55 0.9 % 0.33 [ 0.01, 8.01 ]
Subtotal (95% CI) 55 55 0.9 % 0.33 [ 0.01, 8.01 ]
Total events: 0 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 1271 949 100.0 % 0.50 [ 0.37, 0.68 ]
Total events: 67 (Experimental), 94 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 4.49 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.39, df = 2 (P = 0.82), I2 =0.0%
0.01 0.1 1 10 100
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A D D I T I O N A L T A B L E S
Table 1. ABBREVIATIONS
ABBREVIATION TERM
AIFA Agenzia Italiana Farmaco
CD Crohn Disease
CDER Center for drug evaluation and research (FDA)
CI Confidence Interval
CNS Central Nervous System
CIS Clinically Isolated Syndrome
DMDs Disease-Modifying Drugs
EDSS Expanded Disability Status Scale
EMA European Medicines Agency
FDA Food and Drug Administration
GA Glatiramer Acetate (Copaxone®)
Gd+ Gadolinium enhancing lesion in MRI





IRIS Immune reconstitution inflammatory syndrome
ITT intention-to-treat
IV intravenous
MCS Mental Component Summary (composite scores of SF-36)
MD mean difference
MFIS Modified Fatigue Impact Scale
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Table 1. ABBREVIATIONS (Continued)
MSFC Multiple Sclerosis Functional Composite




NICE National Institute for Clinical Excellence
NNB Number Needed to Benefit
NNH Number Needed to Harm
NNT Number Needed to Treat
NTZ natalizumab
PASAT Paced Auditory Serial Addition Task (one of the components of MSFC)
PCS Physical Component Summary (composite scores of SF-36)
PML Progressive Multifocal Leukoencephalopathy
QoL Quality of Life
SF-36 Short Form 36
VAS Visual Analog Scale
Table 2. Baseline patient characteristics in studies which contributed to primary efficacy outcomes (AFFIRM and SENTINEL)
Characteristic Patients randomised to NTZ
(with or without IFNß-1a)
(n=1216)





Age range 18-55 19-55 18-55
Sex
N of male: N of female
325:891 266:631 591:1522
Disease duration* - years
(range)
1-41 1-34
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Table 2. Baseline patient characteristics in studies which contributed to primary efficacy outcomes (AFFIRM and SENTINEL)
(Continued)
N of patients with 1 relapse in
previous 1 yr (% of total)
758 537 1295 (61)
N of patients with ≥ 2 relapse
in previous 1 yr (% of total)
450 353 803 (38)
N of patients with EDSS ≤ 3.5
(% of total)
1056 769 1825
N of patients with EDSS > 3.5
(% of total)
160 128 288
N of patients with 0 Gd+ (% of
total)
699 544 1243
N of patients with ≥ 1 Gd+ (%
of total)
511 348 859 (41)
Duration ≥ 10 months of pre-
vious IFNß-1a therapy
(% of total)
589 582 1171 (55)
*Definition of disease duration (from the onset? form the diagnosis?) was not available for AFFIRM and SENTINEL trials. We used
time since first MS symptoms for participants in GLANCE trial.
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Other n.a. n.a. n.a. n.a. n.a. n.a. n.a.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1MeSH descriptor Multiple Sclerosis explode all trees
#2MeSH descriptor Demyelinating Diseases, this term only
#3MeSH descriptor Myelitis, Transverse, this term only
#4MeSH descriptor Optic Neuritis explode all trees








#13(#1 OR #1 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14natalizumab OR antegren OR tysabri
#15(#13 AND #14)
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Appendix 2. MEDLINE (PubMed) search strategy
((natalizumab OR antegren OR tysabri))) AND ((((“Multiple Sclerosis”[mh]) OR (“Myelitis, Transverse”[mh:noexp]) OR (“Demyeli-
nating Diseases”[mh:noexp]) OR (“Encephalomyelitis, Acute Disseminated”[mh:noexp]) OR (“OpticNeuritis”[mh])) OR (((“multiple
sclerosis”) OR (“neuromyelitis optica”) OR (“transverse myelitis”) OR (encephalomyelitis) OR (devic) OR (“optic neuritis”)) OR (“de-
myelinating disease*”) OR (“acute disseminated encephalomyelitis”))) AND (((randomized controlled trial[pt]) OR (controlled clinical
trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab]))
NOT ((animals[mh]) NOT ((animals[mh]) AND (human[mh])))))
Appendix 3. EMBASE search strategy
(((’encephalomyelitis’/exp)OR (’demyelinating disease’/exp)OR (’multiple sclerosis’/exp)OR (’myelooptic neuropathy’/exp)OR (’mul-
tiple sclerosis’:ti,ab) OR (’neuromyelitis optica’:ab,ti) OR (encephalomyelitis:ab,ti) OR (devic:ti,ab)) AND ((’crossover procedure’/exp)
OR (’double blind procedure’/exp) OR (’clinical trial’/exp) OR (’controlled clinical trial’/exp) OR (’single blind procedure’/exp) OR
(’randomized controlled trial’/exp) OR (random*:ab,ti) OR (factorial*:ab,ti) OR (crossover:ab,ti) OR (cross:ab,ti AND over:ab,ti) OR
(placebo:ab,ti) OR (’double blind’:ab,ti) OR (’single blind’:ab,ti) OR (assign*:ab,ti) OR (allocat*:ab,ti) OR (volunteer*:ab,ti))) AND
(((’natalizumab’/exp) OR (antegren:ab,ti OR tysabri:ab,ti OR natalizumab:ab,ti))) AND [humans]/lim AND [embase]/lim
Appendix 4. Risk of bias criteria
Item Judgment Description
1 Random sequence generation (selection
bias)
low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimization
high risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability
of the intervention
unclear risk Insufficient information about the sequence generation process to per-
mit judgement of ‘Yes’ or ‘No’
2 Allocation concealment (selection bias) low risk Investigators enrolling participants could not foresee assignment be-
cause one of the following, or an equivalent method, was used to con-
ceal allocation: central allocation (including telephone, web-based, and
pharmacy-controlled, randomization); sequentially numbered drug
containers of identical appearance; sequentially numbered, opaque,
sealed envelopes
high risk Investigators enrolling participants could possibly foresee assignments
because one of the followingmethodwas used: open random allocation
schedule (e.g. a list of randomnumbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or non opaque
103Natalizumab for relapsing remitting multiple sclerosis (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
or not sequentially numbered); alternation or rotation; date of birth;
case record number; any other explicitly unconcealed procedure
unclear risk Insufficient information to permit judgement of ‘Yes’ or ‘No’. This is
usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement
3 Blinding of patients, provider, outcome
assessor (performance bias and detection
bias)
Objective outcomes
low risk Blinding of participants, providers and outcome assessor and unlikely
that the blinding could have been broken;
Either participants or providers were not blinded, but outcome assess-
ment was blinded and the non-blinding of others unlikely to introduce
bias
No blinding, but the objective outcome measurement are not likely
to be influenced by lack of blinding
high risk No blinding or incomplete blinding, and the outcome or outcome
measurement is likely to be influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken;
Either participants or outcome assessor were not blinded, and the non-
blinding of others likely to introduce bias
unclear risk Insufficient information to permit judgement of ‘Yes’ or ‘No’;
4 Blinding of patients, provider, outcome
assessor (performance bias and detection
bias)
Subjective outcomes
low risk Blinding of participants, providers and outcome assessor and unlikely
that the blinding could have been broken;
Either participants or providers were not blinded, but outcome assess-
ment was blinded and the non-blinding of others unlikely to introduce
bias
high risk No blinding or incomplete blinding, and the outcome or outcome
measurement is likely to be influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken;
Either participants or outcome assessor were not blinded, and the non-
blinding of others likely to introduce bias
unclear risk Insufficient information to permit judgement of ‘Yes’ or ‘No’;
5 Incomplete outcome data (attrition bias)
for all outcomes except retention in treat-
ment or drop out
low risk No missing outcome data;
Reasons for missing outcome data unlikely to be related to true out-
come (for survival data, censoring unlikely to be introducing bias);
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk not enough to have a clinically
relevant impact on the intervention effect estimate;
For continuous outcome data, plausible effect size (difference inmeans
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(Continued)
or standardized difference in means) among missing outcomes not
enough to have a clinically relevant impact on observed effect size;
Missing data have been imputed using appropriate methods
All randomized patients are reported/analyzed in the group they were
allocated to by randomization irrespective of non-compliance and co-
interventions (intention to treat)
high risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across
intervention groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate;
For continuous outcome data, plausible effect size (difference inmeans
or standardized difference in means) among missing outcomes enough
to induce clinically relevant bias in observed effect size;
‘As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomization;
unclear risk Insufficient reporting of attrition/exclusions to permit judgement of
‘Yes’ or ‘No’ (e.g. number randomizednot stated, no reasons formissing
data provided; number of drop out not reported for each group);
6 Selective reporting low risk The study protocol is available and all of the study’s pre-specified (pri-
mary and secondary) outcomes that are of interest in the review have
been reported in the pre-specified way;
The study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were pre-
specified (convincing text of this nature may be uncommon)
high risk Not all of the study’s pre-specified primary outcomes have been re-
ported;
One or more primary outcomes is reported using measurements, anal-
ysis methods or subsets of the data (e.g. subscales) that were not pre-
specified;
One ormore reported primary outcomes were not pre-specified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect);
One or more outcomes of interest in the review are reported incom-
pletely so that they cannot be entered in a meta-analysis;
The study report fails to include results for a key outcome that would
be expected to have been reported for such a study
unclear risk Insufficient information to permit judgement of ‘Yes’ or ‘No’
Independent funding source low risk Not sponsored by pharmaceutical industry
high risk Sponsored by pharmaceutical industry
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(Continued)
unclear risk Insufficient information to permit judgement of ‘Yes’ or ‘No’
H I S T O R Y
Protocol first published: Issue 1, 2009
Review first published: Issue 10, 2011
Date Event Description
13 May 2009 Amended The section “Criteria for considering studies for this review” has been amended
10 February 2009 Amended Search strategies
27 October 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Pucci, Giuliani, Solari, Simi and Minozzi drafted the protocol.
Pucci developed the search strategy.
Pucci, Giuliani and Solari performed screening of identified trials for possible inclusion.
Pucci and Galea extracted data from trials.
Pucci, Minozzi and Giuliani assessed methodological quality of each included trial.
Di Pietrantonj checked the extraction, structured the comparisons, entered the data intoReview Manager (RevMan) 2008 andperformed
the analysis.
Pucci and Di Pietrantonj interpreted the analysis.
Pucci, Giuliani, Solari, Simi, Galea, Minozzi and Di Pietrantonj wrote the final report.
Pucci and Di Pietrantonj will update the review.
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External sources
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol, we stated that “adverse event” did not include MS relapses. In the review we included MS relapses in AEs as the original
trials did. Whenever possible, however, we analysed data including and excluding MS relapses.
Incidence of serious AE was moved from secondary outcomes to primary outcomes.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adjuvants, Immunologic [adverse effects; ∗therapeutic use]; Antibodies, Monoclonal [adverse effects; ∗therapeutic use]; Antibodies,
Monoclonal,Humanized; CellMigration Inhibition; Interferon-beta [∗ therapeutic use];Multiple Sclerosis, Relapsing-Remitting [∗drug
therapy]; Peptides [adverse effects; ∗therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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